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Abstract 
 
The CRISPR-Cas (clustered regularly interspersed short palindromic repeats-
CRISPR-associated proteins) immune systems found in many prokaryotes rely on small 
guide CRISPR RNAs (crRNAs) to destroy invading viruses and plasmids. This RNA-
guided adaptive immune response is mediated by numerous diverse Cas proteins, several 
of which form complexes with crRNAs and function to silence foreign nucleic acids. 
Current understanding of the molecular basis of these proteins is limited. Here, we 
present biochemical and structural characterization of two sets of such proteins: Cascade 
from Escherichia coli and Cas9 from Streptococcus thermophilus.  
E. coli Cascade, a large multimeric ribonucleoprotein complex, uses crRNA to 
base pair with complementary DNA (protospacer) at sites adjacent to a signature 
sequence termed the protospacer adjacent motif (PAM). The bound structure, known as 
an R-loop, propagates from PAM to the other end of the protospacer. A crystal structure 
of Cascade bound to a ssDNA target, previously determined by our laboratory, reveals a 
potential pocket for binding of the displaced strand in the R-loop. Here we provide 
experimental evidence that this pocket serves as a docking site for the displaced strand, 
and this binding facilitates DNA strand separation during R-loop formation. Structure-
guided mutagenesis of the basic residues in the pocket confirms their importance for 
double strand DNA binding. Single-molecule experiments reveal that these mutations 
kinetically hinder R-loop formation. We further show that Cascade exerts a strong 
conformational “lock” upon completion of an R-loop, and this locked conformation is 
sufficient for recruiting the trans-acting Cas3 helicase/nuclease for target destruction.    
 
	   iii	  
Cas9 from S. thermophilus LMG18311 is 1122 amino acid protein harboring a 
HNH nuclease domain and a RuvC-like nuclease domain. We demonstrate that 
LMG18311 Cas9 utilizes a crRNA in conjunction with a trans-acting crRNA (tracrRNA) 
to cleave double strand DNA in vivo and in vitro. The cleavage is dependent on the 
presence of PAM as well as the position of the PAM. We further show that the HNH and 
RuvC-like nuclease domains of Cas9 select the location of their cleavage sites via 
different mechanisms. The HNH domain catalyzes cleavage of the target strand at a fixed 
position, whereas the RuvC-like domain catalyzes cleavage of the non-target strand using 
a ruler mechanism. 
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Introduction to CRISPR-Cas systems 
Viruses are the most abundant life form on earth, outnumbering their hosts by ten 
fold (1). Bacteria and archaea are under constant threat from prokaryotic viruses 
(bacteriophages or phages). As a consequence, multiple defense mechanisms have 
evolved in prokaryotes to combat phage infections. Among them, mechanisms to inhibit 
phage adsorption, restriction-modification, and abortive infection systems are some better 
characterized antiviral strategies which provide innate immunity (2). On the other hand, a 
recently identified CRISPR-Cas (clustered regularly interspersed short palindromic 
repeats-CRISPR-associated proteins) system represents a distinct defense mechanism that 
provides adaptive immunity against phage infection as well as plasmid conjugation (3-7). 
The CRISPR-Cas system is widespread; it is present in most archaea and about half of 
the bacteria genomes (8).    
A CRISPR-Cas locus comprises two components: a CRISPR array and a cas 
operon. The CRISPR array consists of a stretch of identical short direct repeats (25-40 
base pairs (bp)) separated by unique invader-derived “spacer” sequences of similar length 
(Mojica et al. 2005; Bolotin 2005; Pourcel et al. 2005). A set of cas genes is usually 
located adjacent to the CRISPR loci and encodes Cas proteins that play essential roles in 
the CRISPR-Cas activity. The immunity mediated by CRISPR-Cas is carried out in three 
stages (Fig 1.1): acquisition of new spacers, generation of small guide CRISPR RNA 
(crRNA), and target interference. In the first stage, prokaryotes adapt to invasive mobile 
elements, such as phages and plasmids, by taking up short DNA fragments (protospacers) 
and integrating into the CRISPR locus as new spacer sequences (5,6). These spacer 
sequences record past exposures and will be utilized against future invasions from the 
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same genetic elements. Secondly, the CRISPR locus is transcribed into a primary 
transcript and processed to generate mature crRNAs that contain spacer-derived 
sequences. Finally, the crRNA, assembled into an effector complex with Cas protein/s, 
directs interference with target nucleic acids in a sequence-specific manner. This usually 
results in target cleavage by the Cas nucleases. As such, CRISPR-Cas is able to mount a 
rapid and robust counterattack against invading genetic elements in prokaryotes.  
The CRISPR-Cas systems are rapidly evolving. Apart from the universally 
conserved Cas1 and Cas2 that are responsible for spacer acquisition, other Cas proteins 
and their functions are vastly diverse (8,9). Based on the configuration of the effector 
complexes, current classification broadly divides CRISPR-Cas systems into two classes: 
class 1 utilizes multiple proteins complexed with crRNA to mediate target recognition 
and degradation, whereas class 2 employs a single large protein in conjunction with 
crRNA to fulfill the function (8) (Fig 1.2). Class 1 systems consist of type I, type III and 
a putative new type IV, and Class 2 systems consist of type II and a putative new type V 
(Fig 1.2) (8). Type I, II and III were previously defined according to the presence of their 
signature proteins: Cas3 for type I, Cas9 for type II, and Cas10 for type III, respectively 
(10) (Fig 1.2); each of these systems can be further divided into subgroups. A detailed 
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Type I systems 
Type I systems are the most prevalent CRISPR-Cas systems among both bacteria 
and archaea (8). Typical type I mediated immunity requires the multi-subunit effector 
complex termed Cascade (CRISPR-associated complex for antiviral defense) and the 
translocating nuclease Cas3. A great body of knowledge of type I systems comes from 
structural and biochemical studies of Escherichia coli type I-E (Fig 1.3). Firstly, Cas1 
and Cas2 comprise a hexameric intergrase complex that uses a cut-ant-paste mechanism 
to incorporate new spacers into the CRISPR array (11,12). In some cases, if a variant of a 
pre-existing spacer is encountered, the interference components Cascade and Cas3 assist 
Cas1 and Cas2 in spacer acquisition (13,14). This process, known as “priming”, is more 
complex yet more effective (15). Next, the Cas6 endonuclease, a subunit of the Cascade 
complex, processes the primary crRNA transcript to produce a 61-nucleotide (nt) mature 
crRNA (16-18). The mature crRNA contains a 32-nt spacer sequence flanked by an 8-nt 
5’ end handle and 21-nt 3’ end hairpin structure (19). Lastly, eleven protein subunits of 
five Cas proteins (Cse11, Cse22, Cas51, Cas61, Cas76) assemble with the crRNA to form a 
Cascade surveillance complex, which recognizes cognate foreign DNA and recruits Cas3 
for target degradation (16,19).  
 
Cascade 
The overall structure of E. coli Cascade was first revealed by electron microscopy 
(EM) (19-21). Three subsequent atomic-resolution crystal structures advanced the 
understanding of this complex (22-24). Overall, the E. coli Cascade resembles a 
seahorse-like architecture (Fig 1.4A and C) in which the 3’ hairpin and 5’ handle of 
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crRNA are capped by Cas6 (head) and Cas5 (tail), respectively, and the spacer sequence 
is spanned along the helical arrangement formed by six Cas7 subunits (spine). The tail is 
further extended by the large subunit Cse1. The two small subunits Cse2 form a 
homodimer, positioned at the inner surface of the Cas7-crRNA spine (belly). 
Interestingly, in the pre-target bound form (22,24) (Fig 1.4A), the spacer sequence of 
crRNA is displayed as six 5-nt segments with every sixth base flipped out. The bases 
from the 5-nt segments are extended outwards, poised for interactions with the target 
DNA strand, whereas the every sixth base is kinked in an angle not suitable for base 
pairing. These kinks are introduced by the protruding long β-hairpins from Cas5 and 
Cas7.2 to 7.6. This observation is consistent with other data showing that target DNA 
mismatches are readily tolerated at every sixth position (25).  
The cryo-EM reconstruction of Cascade before and after binding to a single-
strand (ss) RNA target mimic revealed a concerted conformational rearrangement where 
Cas6, Cse2 dimer and Cse1 shift and rotate along the Cas7-crRNA spine (20). A 3-Å 
crystal structure of Cascade bound to a ssDNA target (Fig 1.4B) confirmed this 
observation (23). In addition, this crystal structure further showed that the crRNA:ssDNA 
heteroduplex adopts a highly distorted A-form architecture that mimics a ribbon. This 
unusual configuration is due to the interruptions from the long β-hairpins of Cas5 and 
Cas7 that prevent base paring at every sixth position. The underwound duplex ensures 
continuous base paring at each 5-nt segments. Such distorted conformation and small 
increments likely serve as a step-wise proofreading mechanism, because nonspecific 
targets that base pair incorrectly with the crRNA can not overcome the energetic cost of 
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Being the signature protein of type I systems, Cas3 typically consists of a HD 
nuclease and a Superfamily 2 helicase. Biochemical studies showed that Cas3 of type I-E, 
upon recruitment by Cascade-DNA binding, nicks the displaced strand and proceeds to 
unwind duplex DNA in a 3’ to 5’ direction using an “inchworm” mechanism (26,27). The 
nuclease activity requires Mg2+ or transition metal ions such as Mn2+ and Ni2+, and the 
helicase activity is dependent on ATP hydrolysis (26-28). Two crystal structures of full-
length type I-E Cas3 have been solved to date, one from Thermobaculum terrenum with 
and without ATP analog bound (29), and one from Thermobifida fusca in complex with a 
ssDNA (30). Both structures showed two metal ions coordinated by conserved residues in 
the HD nuclease domain. ATP binding at the interface of Superfamily 2 helicase RecA-
like domains induces conformational changes in a motif V, suggesting it may be involved 
in coupling ATPase activity with ssDNA binding and translocation (29). The ssDNA-
bound Cas3 structure implies that ssDNA substrate is likely fed into the catalytic site of 
the HD nuclease by the Superfamily 2 helicase (30). In addition, a low-resolution EM 
structure suggested that Cas3 is recruited by Cse1 at the PAM proximal end of the 
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PAM recognition  
Another important prerequisite for target recognition is the presence of a short 
consensus sequence adjacent to the target sequence, termed protospacer adjacent motif 
(PAM) (31). The acquisition machinery selectively incorporates spacers near a PAM 
sequence (14,31). Thus, the presence of PAM signals a non-self DNA, as the genomic 
CRISPR locus lacks a PAM (32). E. coli PAM has a consensus sequence 5’-CWT-3’ 
(where W is an adenosine or thymidine) (31). However, recent studies found that up to 5 
different PAM sequences can be recognized by Cascade for target interference, and about 
22 are functional for priming, making the PAM interaction promiscuous (25). Previous 
work has implied that Cse1 is important for PAM recognition and Cas3 recruitment 
(21,33). Mutations in a loop from Cse1 impaired PAM binding (33). Additionally, the 
base pairing potential of PAM region affects target degradation by Cas3 (21). However, a 
complete understanding of PAM interaction and its role in Cas3 activation awaits detailed 
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Type II systems 
Type II systems constitute a minority of all CRISPR-Cas systems, and they 
appear to be present exclusively in bacteria (8). Notably, type II systems differ 
mechanistically from type I and type III, and have by far the minimal components. Type 
II cas operons typically comprise three to four cas genes, including cas1, cas2, the 
signature gene cas9, and in some cases csn2 or cas4 (Fig 1.2 and 1.5) (8). In addition to 
the cas operon and CRISPR array, type II loci include an atypical gene that encodes for 
trans-activating crRNA (tracrRNA), which is necessary for co-processing of crRNA and 
proper anchoring of crRNA in Cas9 (Fig 1.5).  
Type II systems have evolved a distinct enzymatic pathway. During spacer 
acquisition, besides the functionally conserved Cas1 and Cas2, Cas9 and Csn2 have been 
recently shown to be also required in type II-A (34,35). Specifically, Cas9 appears to 
influence spacer selection by specifying PAM sequences (34). The guide crRNA is first 
cleaved by endogenous RNase III in the partially complementary repeat region of crRNA 
and tracrRNA, and subsequently trimmed by an unknown nuclease (36) (Fig 1.5). The 
resulting mature crRNA contains ~20 nt spacer sequence (36). Cas9, the only protein 
component required for target interference, forms a ternary complex with 
crRNA:tracrRNA duplex, which identifies complementary target DNA in a PAM 
dependent manner and introduces a blunt-end double-strand (ds) DNA break (7,37,38). 
The tracrRNA:crRNA duplex structure is required to activate the nuclease activities of 
Cas9 (36,37).  
The two RNAs can be artificially fused into one single guide RNA (sgRNA), 
which enabled easy implementation of CRISPR-Cas9 as a genome engineering tool (37). 
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By designing the sgRNA, Cas9 nucleases can be programmed to target virtually any 
sequence of interest in the genome. The dsDNA breaks generated by Cas9 can be 
repaired by homologous recombination or non-homologous end joining, which can lead 
to different types of mutations (39-41). In addition, nuclease dead versions of Cas9, 
which bind to but do not cleave the target, have been employed to effectively regulate 
gene transcription (42). However, current research endeavors have been largely based on 
the Streptococcus pyogenes Cas9, and it has reached several limitations. While the 
general mechanism of Cas9-mediated DNA targeting has been unraveled, to develop an 
ideal Cas9-based tool for genome engineering and potentially gene therapy requires 
further studies of this system.   
 
Cas9 
Despite high sequence diversity, the type II signature protein Cas9 typically 
contains a HNH nuclease domain, a RuvC-like nuclease domain, and a characteristic 
Arginine-rich cluster (8) (Fig 1.6A). The HNH and RuvC-like nuclease domains have 
been shown to cleave DNA complementary and non-complementary strands, respectively 
(37,38). Crystal structures of Cas9 from S. pyogenes (type II-A) (Fig 1.6A and B) and a 
smaller ortholog from Actinomyces naeslundi (type II-C) both revealed a bi-lobed 
architecture with HNH, RuvC, and carboxyl-terminal domain (CTD) comprising the 
nuclease (NUC) lobe and an α-helical domain forming the other lobe, later referred to as 
the recognition (REC) lobe (43,44). A recent Cas9 structure of another smaller ortholog 
from Staphylococcus aureus (type II-A) revealed a similar bi-lobed conformation, 
suggesting the structural conservation for all Cas9 enzymes (45). The HNH domain likely 
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uses a one-metal ion catalytic mechanism, whereas the RuvC domain uses a two-metal 
ion mechanism,	   based on structural similarities to known nucleases (37,44,45). 
Comparison with sgRNA or sgRNA:DNA (Fig 1.6C and D) bound structures suggested 
that Cas9 adopts an auto-inhibited conformation in its apo form and undergoes 
conformational changes upon guide RNA binding, and further rearranges upon DNA 
target binding (37,44,46) (Fig 1.6B-D).  
A structure of S. pyogenes Cas9 in complex with sgRNA (Fig 1.6C) indicated that 
guide RNA binding triggers Cas9 to reach a target-recognition competent conformation 
(46). Specifically, guide RNA binding induces structural rearrangement of the NUC and 
REC lobe to form a central groove to accommodate the repeat:antirepeat structure and the 
spacer region of sgRNA. Furthermore, the first 10-nt of the sgRNA spacer region is pre-
organized in an A-form conformation, reminiscent of the RNA positioning in Argonaute 
proteins, suggesting they might use a similar mechanism to engage a DNA target. 
Structures of Cas9-sgRNA bound to DNA targets further provided insights into target 
recognition by Cas9 (Fig 1.6D) (44,47). Overall, the structures revealed additional 
conformational rearrangement of Cas9 from its guide RNA bound state, especially in the 
NUC lobe. The sgRNA;ssDNA heteroduplex adopts an A-form helical structure, 
positioned at the central groove between the NUC and REC lobe, consistent with sgRNA 
bound structure. The conserved Arginine-rich cluster on a helix bridging the two lobes is 
critical for sgRNA:DNA recognition. Comparison between these structures suggested a 
high degree of structural flexibility in Cas9.  
 
 
	   11	  
PAM recognition 
Similar to Cascade, PAM recognition is also a critical aspect for Cas9-mediated 
DNA targeting. Cas9 searches DNA for PAM sequences, and the identification of PAM 
triggers base paring between crRNA and target DNA in a unidirectional manner (48). S. 
pyogenes Cas9 recognizes a 5’-NGG-3’ PAM. Comparison between the apo Cas9 and the 
sgRNA-Cas9 structures showed that guide RNA binding triggers the PAM recognition 
region to become ordered. A structure of S. pyogenes Cas9 bound to a sgRNA and a 
dsDNA target containing a 5’-TGG-3’ PAM provided a close-up view of PAM 
recognition (Fig 1.6D) (47). Consistent with biochemical data, PAM is read out from the 
non-target strand at the GG position (37). The guanine dinucleotide is recognized in the 
major groove by conserved Arg residues from the CTD domain. Additional analysis 
revealed that PAM binding results in dsDNA melting immediately upstream of PAM, in 
agreement with single-molecule data (48). Structural comparison with S. aureus Cas9 in 
complex with sgRNA and dsDNA containing its consensus PAM (5’-NNGRRT-3’) 
suggested that the specific residues in the PAM recognition region determine the distinct 
PAM specificities of Cas9 orthologs (45). These studies furthered the understanding of 
the structural basis of PAM recognition, and will help with the design of versatile Cas9 
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CRISPR-Cas and Public Health 
Recent breakthroughs in discovering the molecular underpinning of CRISPR-Cas 
systems have paved the way for several applications. In particular, Cas9, the 
endonuclease that mediates target interference in type II systems, has attracted great 
attention as a genome engineering tool (39-41). Due to the simple requirements of the 
targeting machinery and the programmable targeting capability, Cas9-based techniques 
have been exploited for a number of emerging biological and medical applications (49-
51). However, the use of the versatile CRISPR-Cas systems is not limited to genome 
engineering. Here, a few public health related perspectives of CRISPR-Cas applications 
are highlighted.  
 
Pathogen typing and subtyping 
Rapid and accurate identification of the source of infection is key to a timely 
response to a microbial outbreak. Differentiation of isolates at a sub-species level, or 
subtyping, presents a challenge to molecular epidemiologists (52). CRISPR provides the 
possibility for a precise and quick molecular typing method of bacterial pathogens. This 
is due to the fact that the spacer sequences in bacterial CRISPR loci are incorporated in a 
polarized manner: the new spacers are added to the 5’ end, or the “leader sequence”, of 
the CRISPR array (5,53). The older spacers, located distal to the leader sequence, may be 
shared among common ancestors. Thus, the spacer sequences can be used to trace the 
evolution of a particular strain. Furthermore, microvariations between strains, such as 
duplication or loss of internal spacers, or single nucleotide polymorphisms in spacers, 
provide additional information for the discrimination below the serotype level (54).  
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CRISPR-based typing methods have been applied for strain discrimination in 
Salmonella, a genus of bacteria that is commonly associated with foodborne illness 
outbreaks (54-56). Analysis of the distribution of over 3,800 unique spacers in 
Salmonella isolates showed that spacer content was strongly correlated with both 
serotype and the multilocus sequence typing type (54). A CRISPR-based high-throughput 
subtyping method has been developed for the most prevalent Salmonella serotype, 
Typhimurium (54). This method is fast, convenient, and highly specific when tested in 
several different Salmonella Typhi strains from diverse genetic and geographical origins. 
These studies demonstrated that CRISPR sequence analysis could be utilized as a 
powerful approach for typing and subtyping of human pathogens, and is likely to be of 
benefit to the public health laboratories.  
 
Antibiotic Resistance 
Bacterial antibiotic resistance has emerged as a serious public health threat. The 
prevalence of antibiotic resistance is largely due to the spreading of antibiotic genes 
between bacteria, a process known as horizontal gene transfer (54). This can occur 
through phage transduction, plasmid conjugation, and DNA transformation (57). 
CRISPR-Cas loci are estimated to exist in about half of human bacterial pathogens, such 
as Staphylococci epidermidis, Streptococcus agalactiae, Escherichia coli and 
Helicobacter pylori, etc. (57). However, the robustness of CRISPR-Cas immunity and the 
emergence of antibiotic resistance appear to be negatively correlated. CRISPR-Cas has 
been shown experimentally to limit horizontal gene transfer events and hence the 
acquisition of virulence or antibiotic resistance genes (58). In addition, a sequence 
	   14	  
analysis of Enterococci revealed an inverse correlation between the presence of CRISPR-
Cas loci and the accumulation of antibiotic resistance genes (57,59). The loss of 
CRISPR-Cas loci has also been reported in several other bacterial pathogens (60). These 
studies suggest that antibiotic use may have driven the selection towards a compromised 
immune system in bacteria in order to gain beneficial traits for their survival, such as 
antibiotic resistance genes.  
Recently, with the development of CRISPR-Cas9 technology, the concept of 
CRISPR-based next-generation antimicrobials has been introduced (61). The basic 
principle is to program Cas9-crRNA to selectively target bacteria harboring specific 
resistance genes. Two recent studies demonstrated the feasibility of this strategy (62). 
Bikard et al. developed a phagemid system that delivers Cas9 and its guide RNA 
sequences to selectively kill antibiotic resistant strains of Staphylococcus aureus. A 
phagemid is a plasmid that is capable of being packaged into phage particles. Incubating 
the phage particles with the S. aureus cells resulted in a survival rate of 10-4. This 
treatment could also immunize the antibiotic sensitive population against plasmid transfer, 
preventing the spread of antibiotic resistance genes. A similar strategy used by Citorik et 
al. to target antibiotic-resistant strains of pathogenic E. coli achieved similar results. 
These studies showed that it is promising to selectively kill or re-sensitize antibiotic-
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Antiviral therapy 
Chronic viral infections affect billions of people worldwide, and there is a dire 
need for a curative antiviral therapy. Current antiviral therapies are effective at targeting 
replicating virus, but they do not eradicate latently integrated or non-replicating proviral 
DNA (63,64). The advance with CRISPR-Cas9 technology has provided the possibility to 
directly target the integrated viral DNA, with the hope of eradicating the entire 
population of viral DNA genomes (65). The first study that explored the antiviral therapy 
potentials of CRISPR-Cas9 technology was carried out by Ebina et al. in human 
immunodeficiency virus type 1 (HIV-1) (66).  Cas9 and its guide RNA were designed to 
target long terminal repeat sequence of HIV-1, which led to significant inhibition of virus 
expression and removal of the integrated proviral DNA from the cellular genome (67). 
Using a similar approach, Hu et al. showed that, in addition to the excision of latent 
proviruses, CRISPR-Cas can also immunize cells against HIV-1 infection (67). This 
work has been extended by others to remove or inactivate DNA genomes of hepatitis B 
virus, human papilloma virus, and herpes simplex virus with varying degrees of success 
(68) Although a targeted curative antiviral therapy is still in its infancy, CRISPR-Cas 
opens up potential new approaches to eradicate viral infections.  
 
Cancer therapy 
Cancer has significant impact on public health in the United States. Given that 
cancer is a genetic disorder, CRISPR-Cas9 can be harnessed to correct the oncogenic 
mutations or modulate epigenetic states. Early attempts using CRISPR-Cas9 to correct 
disease alleles have been reported by several groups in animal models of human disease 
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(66). For example, Xue et al. delivered a plasmid encoding Cas9 and sgRNA via 
hydrodynamic injection to directly target the tumor suppressor genes Pten and p53 in 
mouse liver, which resulted in (~20%) hepatocyte modification (69). This study 
demonstrated the feasibility of generating somatic cancer mutations in adult animals 
using CRISPR-Cas9, which could lead to fast development of animal cancer models. In a 
recent study, Wu et al. transfected spermatogonial stem cells (SSC) with a plasmid 
expressing Cas9 and sgRNA, targeting a disease-causing mutation in Crygc that pre-
existed in SSCs (70). After spermatogenesis in male mice, single SSCs that carry the 
desired gene correction without additional unwanted genomic changes were selected and 
injected into mature oocytes in female mice. This approach yielded offspring with the 
corrected phenotype at an efficiency of 100%, and provided proof-of-concept data of 
curing a genetic disease via CRISPR-Cas9 mediated gene correction in SSCs. Although 
these studies were carried out in animal models, they showed compelling early evidence 










Fig 1. 1 Three stages of CRISPR-Cas immunity. A typical CRISPR locus consists of a 
CRISPR array and adjacent CRISPR-associated (cas) genes (colored arrows). The 
CRISPR array is composed of a leader sequence (grey box) followed by a series of 
identical repeats (black boxes) and unique spacers (colored boxes). In the spacer 
acquisition stage, short segments, called protospacers (green box), are cut (scissors) from 
the invading nucleic acid and incorporated into the leader proximal end (No. 1) of the 
CRISPR array. In the crRNA processing stage, CRISPR array is transcribed in to a long 
primary transcript (pre-crRNA), which undergoes processing and produces mature 
crRNA. During target interference, crRNA assembles with Cas proteins to form an 




Fig 1. 2 Classification of CRISPR-Cas systems. Cas proteins are grouped into the three 
functional stages. Functions of Type IV and type V system components are based on 
homology to similar components of other systems, and have not yet been proven 
experimentally. Circles with dashed lines indicate that the components are not found in 
all subtypes within the given type. LS and SS stand for large subunit and small subunit in 
the effector complex. The SS Cas protein names are not shown because the nomenclature 










Fig 1. 3 The E. coli CRISPR locus and the functions of the Cas proteins.  Cse1 (Cas8), 
Cse2, Cas7, Cas5, Cas6, with a stoichiometry of 1:2:6:1:1, together with a crRNA, 
constitute the CRISPR-associated complex for antiviral defense (Cascade). The colored 
rectangles represent different spacers, and the orange diamonds represent identical 
repeats. The E. coli crRNA contains a 32-nt spacer sequence (blue dashed line) flanked 














Fig 1. 4 Crystal structures of Cascade. (A) Cascade bound to crRNA. (B) Cascade 














Fig 1. 5 A typical type II CRISPR locus. A trans-activating crRNA (tracrRNA) is 
encoded in a type II cas operon. The orange diamond within tracrRNA gene indicates 
degenerated repeat sequence. The 1st cleavage event at the repeat complementary region 
of crRNA and tracrRNA is carried out by RNase III. The asterisk indicates that RNase III 
is not a Cas protein. The 2nd cleavage event occurred at the 5’ end of the crRNA is carried 
out by an unknown nuclease. The mature crRNA contains 20 nt of the spacer derived 













Fig 1. 6 Crystal structures of type II S. pyogenes Cas9. (A) Doman organization of S. 
pyogenes Cas9. (B) Crystal structure of apo Cas9. (C) Crystal structure of Cas9 bound to 
a sgRNA. The dashed box highlights the 10 nt seed region of the guide sequence. (D) 
Crystal structure of Cas9 bound to a sgRNA and dsDNA containing a PAM. The dashed 
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Abstract 
In the type I CRISPR-Cas system, a multisubunit ribonucleoprotein complex 
called Cascade uses its crRNA to detect foreign cognate DNA and recruits a translocating 
nuclease Cas3 to degrade the DNA. Cascade target identification results in formation of 
an R-loop, in which the crRNA hybridizes with the target strand and the non-target strand 
becomes displaced. Here we show that the non-target strand is held by a concave groove 
on the surface of Cascade, and this binding facilitates DNA strand separation during R-
loop formation. Combining structural, biochemical and in vivo data, we show that this 
groove is important for target DNA binding. We demonstrate via single-molecule 
experiments that efficient R-loop formation is impeded by mutations in the groove. 
Finally, we show that R-loop stability is enhanced by a locking mechanism, and the 
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Introduction 
Type I systems are the most prevalent CRISPR-Cas systems, accounting for 60% 
of all CRISPR-Cas systems, and can be further divided into six subtypes (I-A to I-U) (8). 
The common feature of the type I systems is that they all utilize a structurally similar 
effector complex termed Cascade (CRISPR-associated complex for antiviral defense) for 
target recognition and the helicase-nuclease Cas3 for target destruction (16,27,71).   
In the type I-E CRISPR-Cas system from Escherichia coli, Cascade is a 405-
kilodalton (kD) complex comprised of 11 subunits of five Cas proteins (Cse11, Cse22, 
Cas76, Cas51, and Cas61) and a 61-nt crRNA. Target recognition by Cascade requires 
complementary base pairing between the DNA target and the crRNA spacer sequence, as 
well as the presence of a 3 bp protospacer adjacent motif—PAM. The first identified 
PAM for E. coli was 5’-CWT-3’ (where W is an adenosine or thymidine) (31). Detection 
of PAM by Cse1 promotes binding of Cascade to the DNA target and enables the 
formation of an R-loop structure between the crRNA and the dsDNA (33). In the R-loop 
structure, the target DNA strand hybridizes with the crRNA while the non-target strand 
becomes displaced. A “locking” step enhances the stability of the R-loop, and is 
suggested to occur through the conformational rearrangement of Cse1 and Cse2 subunits 
(20,23,72,73). Finally, the trans-acting helicase-nuclease Cas3 is recruited to the complex 
to degrade the DNA (27,71).  
The interaction between Cascade and the dsDNA target has been elucidated by 
both structural and biochemical studies. The crystal structure of a pre-target bound 
Cascade shows that the crRNA spacer region is displayed as six 5-nt fragments in a 
pseudo-A-form configuration on the concave surface generated by the six interwoven 
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Cas7 subunits (22,24). Every sixth nucleotide is flipped out by the protruding long β-
hairpin from Cas5 and Cas7.1-Cas7.5 subunits (22-24). Consistent with this observation, 
the crystal structure of Cascade bound to a ssDNA target reveals that the ssDNA forms a 
non-canonical ribbon-like structure with crRNA, in which base paring is discontinuous at 
every sixth position (23). The target strand is stabilized primarily through Watson-Crick 
hydrogen bonding with the crRNA but also by interactions with the Cse1, Cse2 and Cas7 
subunits (23). By contrast, how Cascade interacts with the displaced strand is less clear. 
One low-resolution cryo-EM reconstruction of Cascade bound to a 72-bp dsDNA target 
suggests that the 5’ end of the displaced strand likely loops around Cse1, allowing Cas3 
to access its cut site (21).  This is supported by previous footprinting experiments, that 
showed that the 3’ end but not 5’ end of the displaced strand is protected by Cascade 
binding (19). These studies help to understand the overall positioning of the displaced 
strand on Cascade. However, direct evidence for the location of the displaced strand 
binding site(s) on Cascade is lacking, nor is the mechanism of R-loop formation fully 
understood.   
We identified a concave groove in the ssDNA-bound Cascade structure that could 
serve as a binding site for 3’ end of the displaced strand (23). This groove is surrounded 
by basic residues from Cse2 and Cas7 subunits (23). Here we present a mutational 
analysis of the putative binding site together with biochemical, single-molecule, and in 
vivo experiments demonstrating the critical role of the basic residues in the displaced 
strand binding. We show that mutating these residues affects Cascade binding to dsDNA 
targets and hinders R-loop formation. These mutations, however, do not affect the overall 
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R-loop stability and subsequent Cas3 recruitment. Our study provides mechanistic 
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Results 
Structural analysis reveals a basic groove for displaced strand 
The structure of ssDNA-bound Cascade (4QYZ) reveals a prominent basic groove 
between Cse2 and Cas7, distinct from the guide RNA-target DNA binding pocket (Fig 2. 
1A). This groove is ~14 Å wide and ~17 Å deep, which could easily accommodate a 
single-stranded nucleic acid. Based on footprinting experiments (19,33), Cascade protects 
the 3’ end of the non-target strand, which maps to a similar position in the structure. 
Consistent with these observations, the groove is also lined with several conserved basic 
residues from Cas7 (Lys34, Lys299, and Lys301) and Cse2 (Arg53, Lys142, Arg143, and 
Arg110).   
Since Cse2 subunits undergo a conformation rearrangement upon target binding, 
we compared the positioning of the Cse2 residues in the pre-target bound structures 
(IVY8 and 4U7U) and those in the target bound structure. Interestingly, the basic 
residues are more dispersedly positioned in the pre-target bound state (Fig 2.1D-F). For 
example, Arg53 on both Cse2.1 and Cse2.2 is tilted outwards, making contact with the 
main chain carbonyl oxygen from Glu4 (Fig 2.1F). Arg143 on Cse2.1 faces back to interact 
with Gln147 (Fig 2.1E). These interactions are absent in the target bound state, and the 
side chains turn into the groove space. Additionally, the side chain of Lys142 on both 
Cse2.1 and Cse2.2 rotates ~90°, becoming nearly perpendicular to the surface, poised for 
interactions. Overall, the basic residues become more structurally aligned in the target 
bound state, forming a prominent positively charged path on the surface of the Cse2 
dimer (Fig 2.1B). Notably, Cse2.1 undergoes a ~10 ° rotation towards the bottom of the 
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groove, causing a 30° turn in the path. This rotational twist may add an extra grip on the 
non-target strand (Fig 2.1B).  
Based on the structural analysis, we hypothesize that the basic groove binds to the 
PAM distal end of the non-target strand during R-loop formation.  
 
The basic groove is important for dsDNA binding 
To test whether the basic groove plays a role in dsDNA binding, we mutated a 
subset of the identified basic residues, namely Cse2 R53E, K142E, R110E, and Cas7 
K34E, and purified Cascade complexes bearing each point mutation. Because there are 
two copies of Cse2 and six copies of Cas7, Cse2 mutations display on both copies and 
Cas7 mutations display on all six copies. The Cascade mutants purify like wild-type 
(WT), and the subunits harboring the mutations are incorporated at a similar level to WT 
(Fig 2.2B and C), suggesting that the mutations do not disturb Cascade complex 
assembly. The co-purified guide RNA was also extracted from each mutant and analyzed 
on a urea denaturing gel (Fig 2.2D). Only RNA from Cse2 R110E shows slight 
degradation, suggesting that this mutant may have a minor defect in shielding the guide 
RNA (Fig 2.2D).   
We next examined the binding activity of these Cascade mutants to a dsDNA 
target containing a PAM and a complementary protospacer sequence. A double-filter 
binding assay was employed to assess the binding affinity of Cascade to DNA. We 
incubated a trace amount of radiolabeled dsDNA with increasing concentrations of 
Cascade, and passed the reactions through nitrocellulose and positively charged nylon 
membranes to collect protein-bound DNA and free DNA, respectively. 250 nM of Cse1 
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was supplemented in all cases to prevent dissociation of Cse1 at low concentrations of 
Cascade, as reported previously (33,74).   
We first tested the function of a 5’-CTT-3’ versus a 5’-CAT-3’. Interestingly, we 
found a 5-fold decrease in the apparent dissociation equilibrium constant (Kd) of DNA 
binding to a 5’-CTT-3’ (1.3 ± 0.7 nM) compared to a 5’-CAT-3’ (6.1 ± 0.4 nM) PAM 
(Fig 2.3A). Furthermore, in our single-molecule magnetic tweezer experiments (detailed 
below), we also observed a ≥ 10-fold difference in the mean time of R-loop formation 
between a 5’-CTT-3’ versus a 5’-CAT-3’ PAM at the same Cascade concentration of 90 
nM (Fig 2.5D). The mean time is still higher when using 90 nM of Cascade and the 5’-
CAT-3’ PAM (Fig 2.5D) versus 10 nM of Cascade and the 5’-CTT-3’ PAM. Thus, the 
5’-CTT-3’ PAM was chosen preferentially for this study.  
Using the double-filter binding assay, we observed an increase in Kd  for all four 
mutants, with ~20-30 fold for Cse2 R53E, Cse2 K142E and Cas7 K34E, and ~200-fold 
for Cse2 R110E (Fig 2.3B left). This result suggests that these residues are important for 
dsDNA binding. To further confirm that these mutations specifically hinder R-loop 
formation during binding, we created a DNA substrate containing a “bubble” at the 
protospacer region to mimic a pre-formed R-loop structure. WT Cascade binds to this 
bubble DNA at a Kd of 0.17 ± 0.02 nM, ~ 8 times tighter than that of the dsDNA (Fig 
2.3B right). This corresponds to a difference in Gibbs free energy of -5.2 kJ/mol, which 
was provided by separating the 32 bp of dsDNA. As expected, all mutants display within 
experimental error WT level of affinity to the bubble DNA. Together, these data indicate 
that these residues are likely involved in R-loop formation, presumably by separating the 
two DNA strands.   
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Mutations in the groove affect in vivo Cascade-mediated immunity  
In order to further evaluate the function of these residues, we set up an in vivo 
CRISPR interference assay using E. coli BL21-AI strains. Plasmids encoding Cascade, 
crRNA and Cas3 were transformed into BL21-AI cells, and their expression was under 
control of a T7 promoter which could be further fine-tuned by L-Arabinose from 0.001 to 
0.2%. After growing in the presence of L-Arabinose and IPTG, the cells were made 
competent and transformed with target plasmids to assess the CRISPR interference 
activity. This assay is similar in principle to previously described plaque assays where 
BL21-AI cells overexpressing type I-E system were challenged with Lambda phages 
(16). Sashital et al. noted that overexpression of this system could allow Cascade to 
overcome stringent binding defects such as PAM mutations, and attenuating the system 
by reducing the amount of inducers (0.02% L-Arabinose and 0.01 mM IPTG) enabled 
distinction between WT interference and defective interference against PAM mutations 
(33). We presumed that defects in non-target strand binding are less severe than PAM 
mutations, so, in order to avoid masking of these defects, we further attenuated the 
system by using 0.002% arabinose and 0.005 mM IPTG.  
Using this assay, we assessed the effects of the groove mutations on Cascade-
mediated immunity. We first evaluated WT-level immune response. Immunity is reported 
as the ratio between the colony forming units (CFU) of a control plasmid (containing no 
protospacer) and that of a target plasmid. Cells expressing WT type I-E system exhibited 
a 50-fold stronger immunity against a WT target plasmid harboring a 5’-CTT-3’ PAM 
and a complementary protospacer versus a control plasmid containing no protospacer 
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(Fig 2.4A). Replacing 5’-CTT-3’ with a 5’-CAT-3’ PAM lowered the immunity (Fig 
2.4A), in agreement with our in vitro observations (Fig 2.3A and Fig 2.5D). Changing to 
a 5’-CGT-3’ PAM completely abolished the immunity (Fig 2.4A). For cells expressing 
mutant Cascade, we observed on average a 10-fold reduction in CRISPR immunity 
against a WT target plasmid, with a pattern mostly mimicking in vitro data (Fig 2.4B). 
Since these mutations do not affect Cascade assembly, we hypothesized that the observed 
reduction in immunity is due to deficiency in DNA binding and possibly Cas3 
recruitment.   
 
Real time R-loop observation reveals defects in R-loop formation but not stability of R-
loop  
In collaboration with Dr. Ralf Seidel’s laboratory (Universität Leipzig, Germany), 
we employed a single molecule magnetic tweezer technique to observe real time R-loop 
formation by E. coli Cascade.  R-loop formation as well as its length and stability can be 
characterized at the single-molecule level using magnetic tweezers, where the amount of 
DNA untwisting upon R-loop formation is detected as previously shown for 
Streptococcus thermophilus Cascade and Cas9 (72,73). Briefly, a 2.1k bp DNA molecule 
containing a protospacer is immobilized on a fluidic cell at one end and attached to a 
magnetic bead at the other. A pair of magnets placed above the cell stretches the DNA. 
Depending on the distance between the bead and the magnet, a range of forces could be 
applied to stretch the DNA to different extents. Moreover, the rotation of the magnets 
allows the supercoiling of the DNA either negatively or positively. When holding the 
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DNA at constant negative supercoiling, the formation of an R-loop by Cascade is seen as 
a change of the DNA length, which is recorded as a function of time (Fig 2.5A).  
Dr. Ralf Seidel and colleagues performed magnetic tweezer experiments using 
purified E. coli Cascade provided by us. They first investigated the R-loop formation by 
Cascade carrying a crRNA fully matching a protospacer sequence containing a 5’-CTT-
3’ PAM (Fig 2.5B). The DNA is first twisted at a low force to generate negative 
supercoiling in favor of R-loop formation. In presence of Cascade, we observed a sudden 
change of DNA length, which is characteristic of an R-loop formation (Fig 2.5B). This 
change of around 150 nm corresponds to a 2.7 turn’s shift of the supercoiling curve, in 
agreement with the formation of a 32 bp R-loop. Next, the DNA was rewound to a 
positive supercoiling state to allow the dissociation of Cascade. Cascade remained bound 
to the DNA at a relative high torque (27 pN nm), confirming the locked state described 
previously (72). However, even under elevated force and maximum torque (36 pN nm), 
they were unable to dissociate Cascade from the DNA. In contrast to S. thermophilus 
Cascade, which has a mean time for dissociation of 3 seconds at a positive torque of 22 
pN nm (72), E. coli Cascade exhibits a much stronger locking mechanism.  
Previously, it has been shown that the locking of S. thermophilus Cascade is 
impaired if mismatches are introduced at the PAM distal end of the protospacer. A patch 
of 4 mismatches decreased the stability of the R-loop by 50% while a 6 mismatches patch 
completely abolished the locking (72). In order to loosen the locking by E. coli Cascade, 
a DNA substrate containing a protospacer with 6 mismatches at the PAM distal end was 
used (Fig 2.5C). In this case, R-loop was induced at a lower force and lower negative 
torque value. The change of 120 nm in the DNA length corresponds to a 1.95 turn’s shift 
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of the supercoiling curve in agreement with the formation of a partial R-loop of 26 bp. 
Furthermore, by twisting back the DNA to a positive supercoiled state we observed the 
dissociation of Cascade during the rotation, and it occurred at very minimum positive 
turns.  
By abolishing the locking step, Dr. Ralf Seidel and colleagues were able to 
remove the Cascade in mild conditions to further statistically study the R-loop formation, 
recording multiple events. They investigated the mean times for R-loop formation on a 
“non-lockable” protospacer containing a CTT PAM at different negative torques (Fig 
2.5D). In contrast to S. thermophilus Cascade, E. coli Cascade does not show any torque 
dependence for R-loop formation, although negative supercoiling is needed to initiate R-
loop. They then assessed the mean time for R-loop formation of four Cascade mutants in 
comparison to the WT at specific negative torque (-7 pN nm) and protein concentration 
(30 nM) (Fig 2.5B). Although all mutants were able to form unlocked R-loops identical 
to those observed with the WT, they all showed a mean time for R-loop formation at least 
doubled, confirming their defects in R-loop formation (Fig 2.5E).  
The ability of each mutant to lock the R-loop was also tested using the fully 
matching protospacer. They found that all Cse2 mutants remained bound as tight as 
observed previously for the WT (data not shown), whereas the mutation K34E in the 
Cas7 subunits showed minor deficiency in locking (Fig 2.5F). At the torque of 27 pN nm, 
they observed a sudden jump of 2.7 turns for Cas7 K34E, indicating the dissolution of the 
32 bp R-loop. The mean time for dissociation of Cas7 K34E mutant was around 500 
seconds at 27 pN nm torque, which is still significantly stronger in comparison to S. 
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thermophilus Cascade. However, it is not clear in what extend this point mutation of 
Cascade backbone is impairing the locking stability.  
 
Mutations in the basic groove do not affect Cas3 recruitment 
The downstream event after Cascade target recognition is to recruit Cas3 helicase-
nuclease for target destruction. We next asked if these mutations affect Cascade’s ability 
to recruit Cas3. We performed a previously described in vitro Cas3 cleavage assay (27). 
We cloned a target plasmid bearing a complementary protospacer and a 5’-CTT-3’ PAM. 
We linearized the plasmid target with the restriction enzyme KpnI, which cuts ~2 kb 
upstream and ~3 kb downstream of the protospacer. It was previously determined that 
Cas3 translocates and cleaves DNA preferentially upstream of the protospacer (27,71). 
Thus, the cleavage product of this substrate by Cas3 is primarily a ~3 kb band (Fig 2.5).  
Firstly, we performed Cas3 cleavage assay at 20 nM of Cascade. We incubated 
Cascade, Cas3 and the target plasmid in the presence of ATP, Mg2+ and Co2+. Following 
incubation, proteins were removed by phenol-chloroform extraction, and the DNA was 
separated on agarose gel and visualized by ethidium bromide staining. Based on the Kd 
values from the double-filter binding assay (Fig 2.3B), only WT is fully bound to the 
target at this concentration. As expected, we observed only robust DNA cleavage for WT, 
but nearly undetectable levels of cleavage for all mutants (Fig 2.5A). This suggests that 
Cas3 recruitment is limited by Cascade binding to the target under this condition. Next, 
we increased Cascade concentration to 1 µM and repeated the Cas3 cleavage assay. At 
this concentration, DNA binding is no longer a rate-limiting step for all mutants. As a 
result, robust DNA cleavage was observed for all mutants, suggesting that these 
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mutations do not affect Cas3 recruitment once they are bound to the DNA (Fig 2.5B). 
This is consistent with magnetic tweezer data that R-loop stability is barely affected by 
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Discussion 
Target recognition is a critical step in CRISPR mediated immunity. In type I 
systems, Cascade is responsible for identifying foreign targets and recruiting the 
translocating Cas3 nuclease. Successful target recognition results in an R-loop formation 
between the crRNA and dsDNA. While the target strand base pairs with the crRNA 
forming a ribbon-like structure (23), the non-target strand become single-stranded, which 
is a key pre-requisite for Cas3 loading. However, the mechanism for displacing the non-
target strand is poorly understood, nor is the path of the non-target strand clear. The 
cryoEM structure of Cascade bound to a dsDNA target suggests the PAM proximal end 
of the non-target strand possibly loops around the four-helix bundle of Cse1 (21). The 
crystal structure of ssDNA-bound Cascade reveals a possible groove for the PAM distal 
end of the non-target strand. In this study, we provide experimental evidence that this 
groove serves as the docking site for the PAM distal end of the non-target strand. The 
data presented here helps to elucidate a detailed mechanism of R-loop formation by 
Cascade.   
Recognition of a PAM motif initiates target binding. E. coli CRISPR PAM was 
first identified by Mojica et al. (31) as 5’-CWT-3’. Subsequent studies have demonstrated 
that both CTT and CAT lead to efficient interference in vitro and in vivo (21,25,27,75). 
However, the functionality of a 5’-CTT-3’ PAM versus 5’-CAT-3’ in E. coli CRISPR 
interference has not been compared experimentally. Our data strongly suggests that E. 
coli K12 Cascade recognizes a CTT PAM more efficiently than a CAT (Fig 2.3A, 2.5A 
and 2.5D). Interestingly, bioinformatics analysis of E. coli spacer precursors shows a 
strong bias to 5’-CTT-3’ when the CRISPR repeats end in CTC, and to 5’-CAT-3’ when 
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the repeats end in CAC (31). In E. coli K12 strain, the repeat sequence is 
CGGTTTATCCCCGCTGGCGC-GGGGAACTC, which suggests that CTT is likely to 
be favored. However, the molecular mechanism of PAM recognition by Cascade still 
remains elusive. A L1 motif from Cse1 is suggested to be involved in PAM interaction 
(33). Mutating F129 and N131 from the L1 motif significantly weakens PAM protection 
on the target strand (33). A crystal structure of Cascade bound to a PAM will be desirable 
for understanding the preference for certain base-pairs at each position.    
After PAM recognition, Cascade unwinds DNA in a unidirectional manner 
(72,73). Interaction with PAM destabilizes the adjacent DNA helix, allowing crRNA to 
probe the seed sequence (position 1-8) (76,77). Molecular dynamics simulation model of 
Cascade bound to dsDNA indicates that a β-hairpin on Cse1 may be involved in 
immediate strand separation after PAM (78). As crRNA continues to base pair with the 
target strand, more non-target strand become displaced. Our data suggests that further 
strand separation is likely facilitated by “trapping” the distal end of the non-target strand 
into the deep groove between Cse2 and Cas7 subunits. Our double-filter binding assay 
shows that mutating the basic residues in the groove results in a ~20-200 fold deficiency 
in binding to dsDNA, but nearly no effects on binding to a bubble DNA (Fig 2.3B). The 
overrepresentation of basic residues in the groove may explain the observed moderate 
defects even when two or six copies of mutations were introduced. Our data is also in 
agreement with previous footprinting data that shows the PAM distal end of non-target 
strand is protected by Cascade (19,33). Stabilizing the non-target strand at a distinct 
binding site away from the crRNA-DNA duplex prevents the re-hybridization of the 
dsDNA and could contribute to the stability of the R-loop structure.  
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Target DNA binding triggers a concerted conformational change of the Cse1 and 
Cse2 subunits in Cascade, which further induces a locking mechanism that is required for 
Cas3 recruitment (20,23,72). Both cryoEM and crystal structure show that upon target 
binding the two Cse2 subunits slide down ~16 Å towards the tail and Cse1 undergoes a 
~30° rotation (20,23). Because the groove mutants bind to the bubble DNA with WT 
affinity (Fig 2.3B), we speculate this conformational movement is not impaired by the 
mutations. As expected, the magnetic tweezer data reveals the mutants only hinder R-
loop formation by kinetic inhibition, but the R-loop stability is not compromised once 
formed (Fig 2.5). This locked conformation appears to be sufficient to recruit Cas3, 
despite the deficiency in non-target strand binding (Fig 2.6). It was previously shown that 
mutations in protospacer stall R-loop formation; however, once the R-loop bypasses the 
mutation, it proceeds to protospacer end and becomes locked, and Cas3 cleaves the target 
like WT, regardless of the mutations (73). Our data supports the bidirectional 
‘‘telecommunication’’ model proposed by Rutkauskas et al. (73) in which the 
conformational lock by Cse2 rearrangement and additional PAM verification by Cse1 
trigger target destruction by Cas3.  
Taken together, our study adds to current understanding of R-loop formation by 
Cascade. Our data suggest that after initial PAM recognition and seed hybridization, 
Cascade uses two distinct binding pockets for target strand and non-target strand binding 
(Fig 2.7). Once the R-loop proceeds towards the PAM distal end of the protospacer, 
Cascade locks the conformation and recruits Cas3 for degradation. The locking 
mechanism, also observed for S. thermophilus Cascade, defines a unique feature for the 
type I-E systems. Our data presents the first direct observation of R-loop formation of E. 
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coli Cascade by the single-molecule magnetic tweezer technique. Consistent with 
previous observations (27,71), our data suggests that E. coli and S. thermophilus Cascade 
complexes function analogously. Both complexes appear to use the same directional R-
loop propagation and locking mechanism to achieve target recognition. Notably, E. coli 
Cascade R-loop formation is torque-independent, and the locking appears to be 
significantly stronger. Due to a lack of structural information of S. thermophilus Cascade, 
it is unclear what contributes to mechanistic differences. Nevertheless, we think the 
















Fig 2. 1 Structural analysis reveals a basic groove for the non-target strand. (A) 
Electrostatic surface representation of Cascade bound to crRNA (orange) and crRNA 
(green) illustrates the basic groove (dashed line) for non-target strand binding. (B) 
Electrostatic surface representation of Cse2 dimer with close-up views of the positively 
charged residues on each monomer.  (C) Overlay of the Cse2 dimer before (gold) and 
after (cyan) binding to a DNA target. (D-F) Close-up views of the identified residues in 
the pre-target bound state.   
 
Fig 2. 2 Selected point mutations do not interfere with complex formation. (A) 
Positions of the selected point mutations in the Cascade structure. Cse2 residues are 
indicated in yellow, and Cas7 residues are indicated in blue. (B) SDS-PAGE of purified 
WT and mutant Cascade. (C) Incorporation of Cse2 (left) and Cas7 (right) subunits for 
the Cascade mutants. The amount of mutated subunit relative to Cas5 was determined 
from SDS-PAGE band intensities and the ratio was normalized against that of WT. 
Aggregate data from three replicates are shown, with error bars representing one standard 


















































































Fig 2. 3 The basic groove is important for dsDNA binding. (A) WT Cascade binding 
curves measured by double filter binding assay. Binding to a target containing a CTT 
PAM is shown in dots, and a CAT PAM in triangles. (B) Bar graph plotting Kd values of 
WT and mutant Cascade binding to a dsDNA substrate (left) and a bubble DNA substrate 
(right), and schematic drawing of the two substrates. Both substrates contain CTT PAM, 
indicated as red bars in the schematic. The bubble DNA was designed such that the 
protospacer region of the non-target strand could not base pair with the target strand.  














Fig 2. 4 in vivo plasmid challenge assay. (A) Relative immunity of E. coli cells 
expressing WT type I-E system against different target DNA. (B) Relative immunity of 
E. coli cells expressing type I-E system with WT or mutant Cascade against a CTT target. 
In both (A) and (B), immunity is calculated as the ratio between the colony forming units 
(CFU)/ug of a control plasmid (scrambled protospacer) versus that of a target plasmid in 
a given trial. Aggregate data from three replicates are shown, with error bars representing 





















































Fig 2. 5 Real time R-loop observation using single molecule magnetic tweezer 
technique. (A) Principle of R-loop detection through single-molecule supercoiling 
(adapted from (73)). DNA molecules are attached to magnetic beads and magnet rotation 
changes DNA supercoiling. R-loop formation causes local DNA unwinding and thus 
overwinding of the adjacent DNA. The grey curve is DNA length plotted against 
introduced turns in absence of an R-loop. The plot is shifted to the left by the number of 
helical turns being unwound by the R-loop (green curve). When DNA is under constant 
negative supercoiling (favorable for R-loop formation), R-loop formation is indicated as a 
DNA length change (green arrow). Similarly, R-loop dissociation is observed at positive 
supercoiling as a similar length change in DNA (red arrow). (B) R-loop formation-
dissociation cycle for a fully matching protospacer with CTT PAM. R-loop formation 
was seen at -7 pN nM (red arrow) but no dissociation was observed even at high positive 
torque (constant orange line). (C) R-loop formation-dissociation cycle for a protospacer 
containing a 6-nt mismatch patch at the PAM distal end.  Cascade release is seen when 
DNA has no negative torque (green line). (D) Time for R-loop formation at different 
torques for DNA targets containing CTT or CAT PAM. Open symbols, CTT PAM; filled 
symbols, CAT PAM. Shape of symbols indicates different Cascade concentration used: 
triangles, 90nM; circles, 30nM, squares, 10nM. (E) Time for R-loop formation by 
Cascade mutants. (F) The locked mutant Cas7.K34E dissociates from DNA at high 



















Fig 2. 6 Cas3 recruitment assay.  Agarose gels of Cas3 recruitment assay with 20 nM 
(A) and 1 μM (B) Cascade. Reaction mixtures containing indicated amount of Cascade, 2 
nM linear plasmid, 300 nM Cas3, 10 mM Mg2+, 100 μM Co2+, and 2 mM ATP were 
incubated for 30 min at 37 °C, followed by phenol chloroform extraction before loaded 
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Materials and Methods  
Cloning and Mutagenesis  
For protein purification, a pBCDE construct containing E. coli cse2-cas7-cas5-
cas7 in the pHAT4 vector,	  a	  pCRISPR-A construct containing CRISPR (7x spacer) and 
E. coli cse1 in the pRSFDuet-1 vector, and a pCse1 construct containing E. coli cse1 in 
the pMAT11 vector were previously generated by Sabin Mulepati. pBCDE and 
pCRISPR-A were used to express Cascade-crRNA. The CRISPR array consists of seven 
identical spacers (sequence: 5’-CCAGTGATAAGTGGAATGCCATGTGGGCTGTC-
3’). pCse1 was used to express Cse1 needed for double-filter binding experiments. 
pCas3a containing E. coli  cas3 in a pSAT1 vector was created by John Mallon.  
For the plasmid challenge assay, a pABCDE-­‐CR construct containing E. coli cse1-
cse2-cas7-cas5-cas7 and CRISPR (7x spacer) in the pACYCDuet-1 vector, a pCas3b 
construct containing E. coli cas3 in the pRSFL vector, and target plasmids in the pBAT4 
vector were prepared by Jasvir Kaila. To generated plasmid targets, synthetic 
oligonucleotides, bearing the appropriate sequence, were annealed and ligated into 
pBAT4 vectors.  
Cascade mutants were created using round-the-horn site-directed mutagenesis. All 
constructs were verified by DNA sequencing. All plasmids used in these studies are 
detailed in Table 2.1. Primers and oligonucleotides used are listed in Table 2.2.  
 
Protein expression and purification 
Proteins were overexpressed in the T7Express strain of E. coli (New England 
Biolabs). Cells were grown in Luria-Bertani (LB) medium supplemented with the 
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appropriate antibiotic(s) (Table 2.1) at 37 °C to an OD600 of 0.3–0.5, and subsequently 
protein expression was induced with 0.2 mM isopropyl-β-D-thiogalactopyranoside 
(IPTG) overnight at 20 °C.  
WT Cascade, Cascade mutants, and Cse1 were purified as described previously 
(74). Briefly, harvested cells were lysed in buffer L (20 mM Tris-HCl, pH 8.0, 100 mM 
NaCl and 10% glycerol), clarified, and then mixed with 5 ml of profinity immobilized 
metal affinity chromatography (IMAC) resin (Bio-Rad). The resin was then washed with 
10 mM imidazole before the protein of interest was eluted with 250 mM imidazole. 
Samples were desalted to remove imidazole and then treated with tobacco etch virus 
(TEV) protease overnight at 4 °C to remove the N-terminal tag. Samples were reapplied 
to IMAC resin to remove the His6-tagged TEV protease, any cleaved tag, or any 
remaining tagged protein. Samples were then concentrated and loaded onto a HiLoad 
26/60 S200 size-exclusion column (GE Healthcare) pre-equilibrated with gel filtration 
buffer (20 mM Tris-HCl, pH 8.0, 200 mM NaCl). Proteins were concentrated to 10 ~ 30 
µM, flash-frozen, and stored at -80 °C.  
For E. coli Cas3 purification, overnight cultures were harvested and immediately 
lysed in buffer L (20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1 mM dithiothreitol (DTT), 
and 10% glycerol). The cell lysate was clarified by centrifugation, and mixed with 5 ml 
of IMAC resin. The resin was washed consecutively with buffer L supplemented with 5 
mM imidazole and then with 1 M NaCl. The remaining bound proteins were eluted with 
buffer L supplemented with 250 mM imidazole. The sample was directly loaded onto a 
HiLoad 26/60 S200 size exclusion column pre-equilibrated in buffer A (20 mM Tris-HCl, 
pH 8.0, 200 mM NaCl, and 1 mM DTT). Fractions containing Cas3 were pooled and 
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treated with SENP protease to remove N-terminal His6-SUMO tag overnight at 4 °C. The 
cleaved sample was then flowed through IMAC resin to remove the His-tagged SENP 
protease, any cleaved tag, or any remaining tagged protein. Samples were then 
concentrated, and loaded onto a HiLoad 26/60 S200 size exclusion column pre-
equilibrated with buffer A. Purified Cas3 was concentrated to ~5 µM, flash-frozen, and 
stored at -80 °C. 
 
crRNA extraction 
crRNA was isolated from Cascade using phenol:chloroform:isoamyl alcohol 
(25:24:1) (Sigma-Aldrich) extraction, followed by ethanol precipitation. RiboLock 
(Thermo Fisher Scientific) was used at 1 unit/ µL to prevent RNA degradation. Isolated 
RNA samples were analyzed on a 10% denaturing TBE gel and visualized by staining 
with SYBR Gold (Invitrogen).  
 
Double-filter binding assay 
Binding of Cascade to DNA was assessed using a double-filter binding assay 
(79). All DNA oligonucleotides were gel-purified. dsDNA or bubble substrates (Table 
2.2) were made by annealing each strand and purified on 12% native polyacrylamide gels 
containing 1× TBE. Trace amounts (10-200 pM) of 5’-end 32P-labled DNA targets were 
incubated with increasing concentrations of Cascade (0-2 µM) for 1 h at 37 °C. Binding 
reactions contained 20 mM Tris-HCl pH 8.0, 100 mM NaCl, 500 nM competitor (Table 
2.2), 0.1 mg/ml bovine serum albumin (BSA), and 10% glycerol. A fixed concentration 
(250 nM) of Cse1 was supplemented to prevent dissociation of Cse1 at low 
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concentrations of Cascade, as determined previously (74). Nitrocellulose (LI-COR) and 
Hybond-N+ nylon (Amersham) membranes were soaked in reaction buffer and 
assembled onto a 10-well (1-inch diameter) vacuum manifold in the order of gel blot 
paper, nylon, and nitrocellulose. After prewashing with 1 ml buffer, 100 µl reaction 
mixture were applied by vacuum, followed by 1 mL of buffer to wash out unbound 
samples. Filter membranes were dried and counted for radioactivity with a scintillation 
counter (Beckman). Data analysis was performed with GraphPad Prism software. 
Reported Kd values are the average of at least three replicates. 
 
Single-Molecule Experiments*   
Single-molecule assays with E. coli Cascade were performed in 20 mM Tris·HCl 
pH 8.0, 100 mM NaCl, and 0.1 mg/mL BSA. Measurements were performed using 30 
nM Cascade unless otherwise indicated. After DNA stretching and initial characterization 
of the DNA, proteins were added, and changes in DNA length were recorded as a 
function of applied force and DNA turns.  
 
Cas3 cleavage assay* 
Cas3 cleavage assays were performed similarly as previously described (27). 
Briefly, the plasmid target containing a 5’-CTT-3’ PAM was linearized using the 
restriction enzyme KpnI. 1 nM linearized plasmid, indicated amounts of Cascade, 300 
mM Cas3, and 2 mM ATP were mixed in a reaction buffer containing 5 mM HEPES pH 
7.5, 60 mM KCl, 10 mM MgCl2, and 100 µM CoCl2. The reactions were incubated at 37 
°C for 30 min and terminated by addition of 20 mM EDTA. The proteins were removed 
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by phenol:chloroform:isoamyl alcohol extraction, and the DNA was separated on 1% 
agarose gels, stained with ethidium bromide, and visualized using FLA-7000 (Fuji).  
 
In vivo transformation assay* 
The recipient strain was generated by co-transforming E. coli BL21-AI cells with 
pABCDE-CR and pCas3b plasmids (Table 2.1). The next day, 2-3 colonies were picked 
and grown in LB medium (supplemented with 0.002% arabinose, 0.005 mM IPTG, as 
well as chloramphenicol and kanamycin) at 37 °C until the OD600  was ~ 0.3. A 5 ml 
culture was used for each plasmid transformation assay. Cells were made competent 
using a previously described CaCl2 heat-shock procedure (99). Cells were pelleted (2,500 
rpm for 10 min) and washed with 3 ml of “Na solution” consisting of 5 mM Tris-HCl 
pH8.0, 100 mM NaCl, and 5 mM MgCl2. Cells were resuspended in 3 ml “Ca solution” 
consisting of 5 mM Tris-HCl pH8.0, 100 mM CaCl2, and 5 mM MgCl2 and incubated on 
ice for 20 min. Cells were pelleted again and resuspended in 200 uL “Ca solution”. Cells 
were then transformed with 80 ng of target plasmid and incubated on ice for another 20 
min. After 45 seconds at 42 °C, cells were added with 800 uL LB and incubated at 37 °C 
for 45 min. Cells were plated with appropriate dilution factors on selection plates. Total 
transformation efficiency was assessed with a plasmid containing scrambled protospacer 
in each assay. Immunity was defined as CFU control plasmid/CFU target plasmid. Reported values 
are the average of at least three replicates.  
 
* The single-molecule experiments were performed by Christophe Rouillon, a post-doc fellow from Dr. 
Ralf Seidel’s laboratory (Universität Leipzig, Germany); Jasvir Kaila, a ScM student (2015-2016) worked 
on the in vivo assay setup, and performed the in vivo experiments with different PAM targets; John Mallon, 
a doctoral student in our laboratory, generated reagents for the in vitro Cas3 recruitment assay and helped 
with assay setup.   
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Table 2. 1 Plasmids used in these studies 
 
 
1: pBCDE and pCRISPR-A are used to express Cascade 
2: pCas3a was used to express Cas3 























Clone Vector Gene/sequence 
pBCDE1 pHAT4 (Ampr) E. coli cse2-cas7-cas5-cas6 
pCRISPR-A1 pRSFDuet-1 (Kanr) MCS1: E. coli cse1;  
MCS2: CRISPR (7x spacer) 
pCse1 pMAT11 (Ampr) E. coli cse1 
pCas3a2 pSAT1 (Ampr) E. coli cas3 
pABCDE-CR3 pACYCDuet-1 (Camr) MCS1: E. coli cse1- cse2-cas7-cas5-cas6; 
MCS2: CRISPR (7x spacer) 
pCas3b3 pRSFL (Kanr) E. coli cas3 
pTarget3 pBAT4 (Ampr) PAM+protospacer 
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                                 Sequence (5’ to 3’) 
 
Primers for round-the-horn mutagenesis 
BR53E forward     AACACCAGCAGGCTCTTTTGCGC 
BR53E reverse      CTGGGTTTTCCCAACCAAAAGG 
BK142E forward   ACGCGAACGCCAGCAACTTCTG 
BR142E reverse    TCTCCCCACCAGGTCAACATCC 
BR110E forward   AAACAGCCGATATGGTCCAGTTAC 
BR110E reverse    CGTCAGCCCGAATTAATTGAAAG 
CR34E forward     AAAGACGAGTAAGAATTTCAAG 
CR34E reverse      CGCCGCCGAAAATAGCGTCTTTC 
 
Oligonucleotides used in double-filter binding assay 
 
T top                     AGCGACTCCCGAGCAATCAGACAGCCCACATGGCATTCCACTTAT 
                              CACTGGCTTGCTTTCGGCTTGCCGCGC 
T bottom               GCGCGGCAAGCCGAAAGCAAGCCAGTGATAAGTGGAATGCCATG 
                              TGGGCTGTCTGATTGCTCGGGAGTCGCT 
T (bubble)1            GCGCGGCAAGCCGAAAGCAAGCTGTCGGGTGTACCGTAAGGTGA 
       bottom            ATAGTGACCTGATTGCTCGGGAGTCGCT 
Competitor top      AGCGACTCCCGAGCAATCACTGTCGGGTGTACCGTAAGGTGAAT 
                              AGTGACCCTTGCTTTCGGCTTGCCGCGC  
Competitor            GCGCGGCAAGCCGAAAGCAAGGGTCACTATTCACCTTACGGTAC 
       bottom            ACCCGACAGTGATTGCTCGGGAGTCGCT 
 
Oligonucleotides used to construct plasmid targets 
 
T forward              CATGGACAGCCCACATGGCATTCCACTTATCACTGGCTT 
T reverse               TCGAAAGCCAGTGATAAGTGGAATGCCATGTGGGCTGTC 
T (ctrl) forward     CATGAGTGATTTGTGCAATGCCTTGTCCGCTGTCAACTT     
T (ctrl) reverse      TCGAAAGTTGACAGCGGACAAGGCATTGCACAAATCACT   







Characterization of a Type II Cas9 from 














* Previously published as  
	  
Chen, H., Choi, J. & Bailey, S., 2014.  
Cut site selection by the two nuclease domains of the Cas9 RNA-guided endonuclease. 
The Journal of Biological Chemistry, 289(19), pp.13284–13294. 
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Abstract 
Cas9, the RNA-guided DNA endonuclease from type II CRISPR-Cas system, has 
been adapted for genome editing and gene regulation in multiple model organisms. In this 
chapter, we characterize a Cas9 ortholog from Streptococcus thermophilus LMG18311 
(LMG18311 Cas9). In vitro reconstitution of this system confirms LMG18311 Cas9 
together with a trans-activating RNA (tracrRNA) and a CRISPR RNA (crRNA) cleave 
dsDNA with a specificity dictated by the sequence of the crRNA. Cleavage requires not 
only complementarity between crRNA and target but also the presence of a short motif 
PAM. Here we show that both the efficiency of DNA target cleavage and the location of 
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Introduction 
A promising tool for genome manipulation (39-41,80-90) and regulation (42,91-
93) in a wide variety of organisms has recently been identified in the RNA-guided DNA 
endonuclease activity of the type II CRISPR-Cas systems. Programmed DNA cleavage 
requires the fewest components in the type II CRISPR-Cas system, requiring only 
crRNA, tracrRNA and the Cas9 endonuclease (37,38), the signature gene of the type II 
system. The system can be further simplified by fusing the mature crRNA and tracrRNA 
into a single guide RNA (sgRNA) (37). In addition to its role in target cleavage, 
tracrRNA also mediates crRNA maturation by forming RNA hybrids with primary 
crRNA transcripts, leading to co-processing of both RNAs by endogenous RNase III 
(36). Cas9 contains two nuclease domains that together generate a double-strand break in 
target DNA. The HNH nuclease domain cleaves the complementary strand and the 
RuvC-like nuclease domain cleaves the non-complementary strand (37,38).  
A short signature sequence, named the protospacer adjacent motif or PAM, is 
characteristic of the invading DNA targeted by the type I and type II CRISPR-Cas 
systems. The PAM serves two functions. It has been linked to the acquisition of new 
spacer sequences and it is necessary for the subsequent recognition and silencing of target 
DNA, reviewed in (94). The sequence, length and position of the PAM vary depending 
on the CRISPR-Cas type and organism. PAMs from type II systems are located 
downstream of the protospacer and contain 2 to 5 bps of conserved sequence. A variable 
sequence, of up to 4 bps, separates the conserved sequence of the PAM from the 
protospacer. This variable region is often included in the definition of the PAM sequence, 
but for simplicity, we refer to this variable region as the linker and the conserved 
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sequence as the PAM. To date, Cas9 from Streptococcus pyogenes, Streptococcus 
thermophilus DGCC7710 and Neisseria meningitidis have been employed as tools for 
genome editing or regulation. For these Cas9 orthologs the PAMs are GG, GGNG and 
GATT, and the linkers are 1, 1 and 4 bps, respectively (37,95,96). 
The simplicity of sgRNA design and sequence specific targeting means the RNA-
guided Cas9 machinery has great potential for programmable genome engineering. Cas9 
can be employed to generate mutations in cells by introducing dsDNA breaks. The 
capabilities of Cas9 can be expanded to various genome engineering purposes, such as 
transcription repression or activation, with its nickase (generated by inactivating one of 
its two nuclease domains) or nuclease null variants (42,92,93,97). Another appealing 
possibility for the Cas9 system is to target different Cas9-mediated activities to multiple 
target sites, for example transcriptional repression of one gene but activation of another 
(98). To achieve this, multiple Cas9 orthologs will need to be employed, as a single 
ortholog cannot concurrently mediate different activities at multiple sites (98). Therefore 
to broaden our understanding of Cas9 proteins, we have characterized the Cas9 ortholog 
from Streptococcus thermophilus LMG18311, which we refer to as LMG18311 Cas9. 
We choose to investigate Cas9 from this organism not only to increase the repertoire of 
Cas9 orthologs but also because it utilizes a PAM distinct from those previously 
characterized and its small gene size is compatible with the standard viral vectors used 
for delivery into exogenous systems in vivo (98).  
Here we demonstrate that requirements for DNA cleavage in vitro and in vivo by 
LMG18311 Cas9 are the same as other Cas9 orthologs. We also reveal the sequence and 
linker length requirements of the PAM for LMG18311 Cas9. Finally, we show that the 
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HNH and RuvC-like nuclease domains of Cas9 select the location of their cleavage sites 
via different mechanisms. The HNH domain catalyzes cleavage of the complementary 
strand at a fixed position, whereas the RuvC-like domain catalyzes cleavage of the non-
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Results 
Identifying the PAM for LMG18311 Cas9  
The genome of S. thermophilus LMG18311 contains two CRISPR-Cas systems, 
of type II-A and III-A, each associated with a CRISPR loci: CRISPR-1 and CRISPR-2, 
respectively. The first study of PAM sequences identified a putative PAM for S. 
thermophilus as RYAAA (where R is a purine and Y a Pyrimidine) (4). This sequence 
was found in natural target sequences matching 41 spacers collected from 13 different S. 
thermophilus strains, including LMG18311. Subsequent studies showed PAM sequences 
vary greatly, even between different strains, reviewed in (94). Therefore to confirm the 
PAM sequence for LMG18311 Cas9, we performed BLAST searches to identify potential 
protospacers in viral and plasmid genomes that matched any of the 33 spacer sequences 
from CRISPR-1. This search generated 41 unique target sequences, from the genomes of 
bacteriophage known to infect S. thermophilus. We then aligned 50-nucleotide segments 
from the identified target genomes, inclusive of the 30-nucleotide protospacer and 10-
nucleotide flanking regions (Fig 3.1B). In agreement with the previous study (4), 
inspection of this alignment clearly identified a 5 bp PAM with a consensus sequence, 
GYAAA, invariantly located 2 bps downstream of the protospacer (Fig 3. 1B and C). The 
most commonly observed PAM sequence, found in 7 or the 41 target sequences, was 
GCAAA. 
To confirm the identified PAM was functional we used a previously described 
transformation assay in which E. coli cells containing an exogenous type II CRISPR-Cas 
system are resistant to plasmid transformation, while cells lacking the system are 
competent for transformation (99,100) (Fig 3.2A). To generate cells containing the type 
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II CRISPR-Cas system (CRISPR+ cells), compatible vectors encoding either LMG18311 
Cas9 or its cognate sgRNA, engineered to contain a 20-nucleotide sequence derived from 
the first spacer of CRISPR-1 (Fig. 1C), were co-transformed into E. coli BL21 (DE3). In 
this overexpression system the Cas9 and sgRNA genes are under the control of an IPTG 
inducible T7 promoter. Control cells lacking the CRISPR-Cas system (CRISPR- cells) 
were generated by co-transforming compatible empty vectors into E. coli BL21 (DE3). 
We constructed a target and two control plasmids. The target plasmid contained 
protospacer-1 (whose sequence was identical to the first spacer of CRISPR-1), a 2 bp 
linker and the identified PAM (GCAAA) (Fig 3.1C). The first control plasmid contained 
only protospacer-1, while the second control plasmid lacked both protospacer-1 and 
PAM. The target and control plasmids were then tested for CRISPR-Cas silencing by 
transformation into the CRISPR+ and CRISPR- strains in the presence of IPTG and the 
appropriate antibiotics (Fig 3.2A). The control plasmids transformed into both strains 
with similar efficiency (Fig 3.2B). The target plasmid failed to transform into the 
CRISPR+ cells but transformed into the CRISPR- cells with an efficiency comparable to 
that of the control plasmids (Fig 3.2B). All of the transformation efficiencies were 
comparable to those previously reported (100). These results indicate that the identified 
PAM is functional in vivo and that the type II CRISPR-Cas system of S. thermophilus 
LMG18311 protects E. coli cells from transformation by plasmid DNA. 
 
Both the PAM sequence and linker length are important for plasmid interference  
To investigate the PAM sequence requirements for LMG18311 Cas9, we 
transformed a series of plasmid targets harboring single-nucleotide mutations throughout 
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the PAM sequence in the CRISPR+ strain (Fig 3.2C). Only the plasmid containing a 
mutation at the position 1 guanosine (that is, the PAM nucleotide closest to the 
protospacer) was transformed, albeit with a reduced (~66%) transformation efficiency 
compared to the intact PAM sequence (Fig 3.2C). Plasmids containing single mutations 
to any of the other four positions were resistant to transformation (Fig 3.2C). These 
results indicate that the guanosine at position 1 is important for PAM function but 
individually the four other positions have little effect on PAM function.  
A 2 bp linker separates the protospacer from the PAM for LMG18311 Cas9 (Fig 
3.1B and C). To investigate how linker length affects Cas9 activity, we generated plasmid 
targets with linkers ranging from 0 to 5 bps in length (Fig 3.2D). We then determined the 
transformation efficiency for these plasmids into the CRISPR+ cells. The CRISPR+ cells 
were equally resistant to transformation by a plasmid target with either a linker length of 
2 or 3 bps (Fig 3.2D). Plasmids with other linker lengths transformed with efficiencies 
more similar to the control plasmid (Fig 3.2D) suggesting that plasmids with these linkers 
were able to escape CRISPR-Cas silencing.  
 
In vitro reconstitution recapitulates in vivo activity 
To further investigate the requirements of PAM sequence and linker length, we 
reconstituted the activity of LMG18311 Cas9 in vitro. LMG18311 Cas9 was expressed 
and purified from E. coli (Fig 3.1A). A 42-nucleotide tracrRNA mimicking the processed 
tracrRNA, and a 42-nucleotide crRNA containing sequence derived from the first spacer 
of CRISPR-1 (Fig 3.1C), were chemically synthesized. Plasmid targets were incubated 
with Cas9, tracrRNA and crRNA and then analyzed by electrophoresis through agarose 
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gels and ethidium bromide staining. As observed for other Cas9 orthologs, cleavage of 
the plasmid target occurred in the presence of Cas9, tracrRNA, crRNA and Mg2+ (Fig 
3.3A). Cleavage also occurred when an sgRNA was substituted for the tracrRNA and 
crRNA (Fig 3.3B). As expected, cleavage was dictated by the sequence of the sgRNA 
(Fig 3.3C). Also, Cas9 variants with active site mutations in either the RuvC-like domain 
(D9A) or HNH domain (H599A) nicked the plasmid targets, while a variant with a 
double mutation (D9A, H599A) displayed no activity (Fig 3.3D). Cleavage assays using 
short oligonucleotide substrates confirmed that the HNH domain cleaves the strand 
complementary to the guide RNA, while the RuvC-like domain cleaves the non-
complementary strand (Fig 3.3E). Mapping the location of the cut sites revealed that, as 
seen with other Cas9 orthologs (7,37,38,101), cleavage of both strands occurs within the 
protospacer, 3 bps from its PAM proximal end, producing a blunt-end dsDNA break (Fig 
3.3E). 
We next wished to confirm that either mutations in the PAM or that changes in 
linker length had the same effect on DNA interference in vitro as they did in vivo. 
Therefore, we monitored cleavage of these variant plasmids by recombinant LMG18311 
Cas9. The fraction plasmid cleaved was calculated using the procedure detailed in the 
Materials and Methods section, which accounts for the different binding affinity of 
ethidium bromide to linear and supercoiled DNA. Consistent with the in vivo results 
mutation of the guanosine at position 1 had the greatest effect, individual mutations to the 
other four positions of the PAM had only a modest effect on plasmid cleavage (Fig 3.3F). 
Cleavage of plasmid targets with different linker lengths was optimal at 2 or 3 bps and 
then decreased steadily with increasing or decreasing lengths (Fig 3.3G).   
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Metal dependency of DNA cleavage by Cas9  
To evaluate whether other divalent cations besides Mg2+ can activate DNA 
cleavage by Cas9, we performed plasmid cleavage assays in the presence of one of the 
following divalent cations: Ca2+, Mn2+, Co2+, Ni2+ and Cu2+. Reactions containing Ca2+ 
yielded nicked, instead of linear plasmid (Fig 3.4A), suggesting that Ca2+ activates only 
one of the Cas9 nuclease domains. To identify which domain was activated, we assayed 
the single active site mutants of Cas9 (D9A or H599A) in a reaction buffer containing 
Ca2+. We observed little cleavage with the HNH mutant (H599A) but robust cleavage 
with the RuvC-like mutant (D9A) (Fig 3.4B), suggesting that the HNH but not the RuvC-
like domain was activated by Ca2+. None of the other divalent cations tested activated 
either nuclease domain of Cas9 (Fig 3.4A).  
 
Both the PAM sequence and the linker length are important for target binding  
Previous studies indicate that mutations within the PAM impair DNA cleavage by 
Cas9 due to weakened binding (37,38,48). To determine the effect of PAM sequence and 
linker length on binding of LMG18311 Cas9 to DNA targets, we determined the binding 
affinity (Kd) of the Cas9-sgRNA complex to 5’-end labeled dsDNA targets using native 
gel electrophoresis (Fig 3.5A). Binding experiments were conducted with the nuclease 
deficient mutant of Cas9 (D9A, H599A) in the presence of Mg2+. Fixed concentrations of 
the dsDNA targets were incubated with increasing concentrations of the Cas9-sgRNA 
complex (Fig 3.5A). A target containing a complementary protospacer, a 2 bp linker and 
a functional PAM bound to Cas9-sgRNA with an affinity of 0.94 ± 0.27 nM (Fig 3.5B). 
	   65	  
We were unable to detect binding to a target containing a non-complementary 
protospacer or to a target that lacked a PAM. Mutation of the guanosine at position 1 of 
the PAM resulted in an ~100-fold increase in Kd (Fig 3.5B), whereas mutations at 
positions 2 through 5 did not significantly alter the affinity (all within ~4-fold on the 
consensus PAM) (Fig 3.5B). Changes in linker length had a larger effect on binding 
affinity (Fig 3.5C). Under the condition tested, we failed to detect binding to plasmid 
targets containing linker lengths of 0, 4 or 5 bps (Kd > 1000  nM), while linkers of 1 and 
3 bps reduced the affinity by ~400-fold and ~20-fold, respectively (Fig 3.5C). 
 
HNH and RuvC-like domains determine the location of their cut sites using different 
mechanisms  
Previous studies reported Cas9 cleaves both DNA strands within the protospacer, 
3 bps from its PAM proximal end, producing a predominantly blunt-end dsDNA break 
(7,37,38,101). To determine if linker length has any effect on where the Cas9 nuclease 
domains cut, we mapped the location of the cut sites in plasmids containing protospacer-1 
and different lengths of linker. Following cleavage by Cas9 (programmed with an sgRNA 
complementary to protospacer-1), the linear plasmid products were purified by agarose 
gel electrophoresis and sequenced. Sequencing data revealed that the position of the 
cleavage site on the non-complementary strand, but not on the complementary strand, 
depended on linker length (Fig 3.6A). Cleavage of the complementary strand always 
occurred 3 nucleotides from the 5’ end of the protospacer sequence, independent of the 
linker length (Fig 3.6A). In contrast, cleavage of the non-complementary strand occurred 
predominantly 5 nucleotides from the 3’ end of the PAM with linker lengths of 2 or more 
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bps or at 4 and 5 nucleotides from the 3’ end of the PAM with a linker length of 1 bp (Fig 
3.6A). The site of cleavage on both strands of the DNA target was also found to be 
independent of spacer sequence. The location of Cas9 cut sites in plasmids containing 
protospacer-2 was found to be identical to plasmids containing protospacer-1 for all 
linker lengths investigated (Fig 3.6B). We were unable to generate enough cleaved DNA 
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Discussion 
Cas9, the RNA-guided endonuclease from the type II CRISPR-Cas system, has 
the potential to revolutionize our ability to manipulate the genomes of a wide variety of 
organisms (39-42,80,81,83-93,102). Targeting Cas9 to specific genomic sites relies on 
the presence of a PAM and complementarity between the sequence of its crRNA and the 
protospacer. A remarkably diverse set of PAM sequences are recognized by Cas9 
orthologs (98). To date, PAM recognition and DNA cleavage have been experimentally 
studied in only a handful of Cas9 orthologs (37,38,96,98). Characterization of additional 
orthologs is expected to improve our mechanistic understanding of Cas9 and likely 
expand our engineering capabilities. Here we present characterization of the Cas9 protein 
from S. thermophilus LMG18311.  
We demonstrate LMG18311 Cas9 is active in vivo through transformation assays 
(Fig 3.2) and in vitro by monitoring plasmid cleavage (Fig 3.3). We also confirm the 
PAM for LMG18311 Cas9 identified by sequence alignments is functional (Fig 3.1B). As 
observed for other Cas9 orthologs, LMG18311 Cas9 activity requires tracrRNA, crRNA 
and Mg2+ (Fig 3.3). Metal ion substitution studies also reveal Ca2+ likely activates the 
HNH but not the RuvC-like domain of LMG18311 Cas9 (Fig 3.4B). Here however we 
cannot rule out the possibility that the observed activation of the HNH domain may be 
due to trace Mg2+ contamination in the Ca2+ solution. Neither nuclease domain of S. 
pyogenes Cas9 is activated by Ca2+ (37).  
Cas9 orthologs have been reported to cleave target DNA with a wide range of 
mutations in the PAM sequences (98). Yet, in natural targets PAM sequences are highly 
conserved. This apparent discrepancy may arise from the dual function of the PAM 
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(94,98). The stringency on the PAM sequence is greater for spacer acquisition than for 
DNA cleavage by Cas9. Consistent with this, our results show that although the PAM for 
LMG18311 Cas9 is conserved (Fig 3.1B), the nuclease activity of LMG18311 Cas9 
tolerates a broad range of mutations in the PAM of the target DNA. Mutations to the 
guanosine at position 1 impair Cas9 activity, while individual mutations at positions 2 
through 5 have little effect. The PAM for N. meningitides Cas9 also contains a single 
guanosine important for Cas9 activity. In addition, two recent in vivo studies show an AG 
sequence can partially replace the consensus PAM, GG, for S. pyogenes Cas9 (88,103). 
Thus, despite the varying sequence of PAM, Cas9 proteins from LMG18311, S. pyogenes 
and N. meningitides all contain a guanosine that appears essential for DNA silencing in 
vivo.  
A previously unexplored aspect of target binding and cleavage by Cas9 is the 
length of the linker between the PAM and protospacer. The 41 natural targets of 
LMG18311 Cas9 we identified in our sequence searches all contain a 2 bp linker. 
However, we found that DNA containing a 3 bp linker was silenced with the same 
efficiency as that with a 2 bp linker (Fig 3.2D and 3F). Further lengthening or shortening 
of the linker eliminates CRISPR-Cas silencing and inhibits plasmid cleavage (Fig 3.2D 
and 3F). Thus, our results on the Type II system of S. thermophilus LMG18311 suggest 
the requirements for the length of the linker appear to be less stringent for DNA silencing 
than for spacer acquisition, a pattern similar to that observed for requirements on the 
PAM sequence.  
Recognition of target DNA by either Cas9 or effector complexes from the Type I 
CRISPR-Cas systems is thought to be a multistep process (33,37,38,48,77). First, cellular 
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DNA is scanned for PAM sequences. Once a PAM is identified, the adjacent DNA 
duplex is destabilized enabling Cas9 to probe sequence complementarity on the target 
strand. Target recognition is completed if this adjacent sequence contains a protospacer 
that can base pair with the crRNA, stabilizing the complex. If this sequence lacks a 
protospacer, then the crRNA-DNA heteroduplex fails to form and Cas9 dissociates. We 
found the affinity of LMG18311 Cas9-sgRNA for its target sequence is ~1.0 nM (Fig 
3.5), which is similar to the Kd of ~0.5 nM reported for S. pyogenes Cas9 (48), and 
comparable to the affinity of the Type I effector complexes for their DNA targets 
(18,74,76). Targets lacking a PAM had no detectable affinity for Cas9. As expected 
(37,38), the impaired nuclease activity of LMG18311 Cas9 observed when PAM 
sequences are mutated arises from the weakened binding affinity between Cas9 and target 
DNA (Fig 3.5B). Further analysis also revealed that the inhibition of cleavage of targets 
with different linker lengths was also due to weakened affinity (Fig 3.5C). Although both 
PAM and linker mutations result in reduced target affinity, they likely affect different 
steps in binding. PAM mutations inhibit the initial recognition of a target sequence, 
whereas, altering linker length likely impairs the efficiency of base pairing between 
crRNA and the protospacer, thus destabilizing the complex. 
The length of the linker between the PAM and protospacer affects both the 
efficiency of DNA target cleavage and the position of the cleavage sites. This suggests 
the two nuclease domains of Cas9 select their cleavage sites by different mechanisms. 
The HNH domain cleaves the complementary strand at a fixed position while the RuvC-
like domain, employing a ruler mechanism, cleaves the non-complementary strand at a 
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position measured from the PAM (Fig 3.6). These observations suggest the domain 
architecture of Cas9 is highly flexible.  
Crystal structures of S. pyogenes and Actinomyces naeslundii Cas9 (43) and of S. 
pyogenes Cas9 in complex with sgRNA and its ssDNA target (44) reveal Cas9 adopts a 
two-lobed architecture composed of target recognition and nuclease lobes. The target 
recognition lobe is essential for binding the sgRNA and the complementary strand of the 
DNA target. The nuclease lobe contains a carboxyl-terminal domain implicated in PAM 
binding (43,44) as well as the HNH and RuvC-like nuclease domains. This structural 
organization is consistent with the two nuclease domains of Cas9 selecting their cleavage 
sites by different mechanisms. In the nuclease lobe, the PAM interacting and RuvC-like 
domains adopt a fixed position relative to each other consistent with our observation that 
cleavage of the non-complementary strand by the RuvC-like domain occurs at a fixed 
distance from the PAM (Fig 3.7). In contrast, the position of the HNH domain is highly 
mobile (43,44). In the current structure of Cas9-sgRNA bound to ssDNA the HNH 
domain is positioned away from its cleave site on the complementary strand (44). During 
cleavage the HNH domain must engage this strand and therefore must dock with the 
target recognition lobe (Fig 3.7). This docking likely determines the cleavage site of the 
HNH domain in the complementary strand. This is consistent with our observation that 
the HNH domain cleaves at a fixed position when the linker length is varied as the 
mobility of the HNH domain and the flexibility between the two lobes of Cas9 (43,44) 
likely accommodate the change in linker length (Fig 3.7). 
In summary, we have characterized the substrate requirements of LMG11831 
Cas9 both in vivo and in vitro. Our results enable wider target selection for genome 
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manipulation through the use of a distinct PAM. They also reiterate the importance of 
considering which Cas9 ortholog to use in genome manipulation, as those with longer 
PAM sequences are not necessarily more stringent in DNA cleavage. We also reveal the 
requirements for linker length in DNA cleavage by a Cas9 ortholog and, by varying the 
linker length, reveal that the two nuclease domains of Cas9 select their cut sites by 






























Fig 3. 1 The Type II CRISPR-Cas system of S. thermophilus LMG18311. (A) 
Coomassie stained SDS-polyacrylamide gel of Cas9, Cas9 D9A, Cas9 D599A and Cas9 
D9A/D599A. (B) Logo plot revealing the PAM for LMG18311 Cas9. The position of the 
protospacer, PAM and linker are indicated. (C) Schematic representation of the crRNA 
(green), tracrRNA (blue) and DNA target (black). The position of the protospacer, PAM 
and linker are indicated. The site at which the crRNA and tracrRNA are fused to generate 



























Fig 3. 2 LMG18311 Cas9 and cognate sgRNA can provide resistance to plasmid 
transformation in E. coli. (A) Schematic representation of transformation assay. (B) 
Interference of plasmid transformation by LMG18311 Cas9 and sgRNA in E. coli cells. 
Transformation efficiency is expressed as cfu per 5 ng of plasmid DNA. Average values 
from at least three biological replicates are shown, with error bars representing one 
standard deviation. (C) Effect of mutation in the PAM sequence on plasmid 

















Fig 3. 3 DNA cleavage by LMG18311 Cas9 in vitro. (A) RNA-guided cleavage by 
Cas9. Reactions mixtures containing 5 nM target plasmid, 25 nM Cas9, 25 nM crRNA, 
25 nM tracrRNA and 10 mM Mg2+ were incubated for 30 min at 37 °C. (B) A cognate 
sgRNA can substitute for crRNA and tracrRNA. (C) Cleavage of a plasmid target is 
dictated by the sgRNA sequence. (D) Cleavage of a plasmid target by active site mutants 
of Cas9. (E) Cleavage of a synthetic dsDNA by active site mutants of Cas9. The dsDNA 
was radiolabeled at the 5’-end of the complementary strand (left) or the non-
complementary strand (right). Reactions were performed as in A, and products separated 
by 10% denaturing PAGE. The cleavage sites are indicated with arrows in the schematic 
diagram (bottom). (F) Cleavage of plasmid targets containing mutations in the PAM 
sequence. (G) Cleavage of plasmid targets containing indicated linker length. Average 
values from at least three biological replicates are shown, with error bars representing one 
standard deviation. In A-C and E-F, the position of negatively supercoiled (nSC), linear 
(L) and nicked or open circle (OC) plasmid is indicated. The linear control is a digestion 


































Fig 3. 4 Metal dependency of DNA cleavage by Cas9.  (A) Cleavage of a target 
plasmid by Cas9 with either no metal or 1 mM of the indicated metal ions. All reactions 
were treated with 0.5 mM EDTA prior to metal addition. (B) Cleavage of a target 
plasmid by active site mutants of Cas9 in the presence of 10 mM Ca2+. In both panels, the 
position of negatively supercoiled (nSC), linear (L) and nicked or open circle (OC) 
plasmid is indicated. The linear control is a digestion of the plasmid target with the 


































Fig 3. 5 DNA target binding by Cas9. (A) A representative gel shift assay for Cas9-
sgRNA and the binding curve measured from the assay. (B, C) Bar graph plotting Kd 
values for (B) DNA targets with PAM mutations (labeled red) or (C) DNA targets with 
different linker lengths (labeled red). Average values from at least three replicates are 
shown, with error bars representing one standard deviation. Targets where binding was 






















Fig 3. 6 Mapping the Cas9 cleavage sites in plasmid targets with different linker 
lengths. Direct sequencing electropherograms for plasmid-sp1 (A) and plasmid-sp2 (B) 
from complementary strand primer (bottom left) and non-complementary strand primer 
(bottom right) are shown. Termination of primer extension in the sequencing reaction 
reveals the position of the cleavage site (red line). The position of the protospacer, PAM 
and linker are indicated. The 3’ terminal A addition, indicated by asterisk, is an artifact of 









































Fig 3. 7 Schematic representation of the cut site selection by HNH and RuvC-like 
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Materials and Methods 
Identification of the PAM  
Natural target sequences were found using the program BLAST. A single 
mismatch was allowed between the spacer and target sequences. Allowing more 
mismatches did not increase the number of sequences found. Sequences were considered 
unique if they were from distinct target genomes. 
 
Cloning and mutagenesis  
The sequence encoding full-length Cas9 was PCR-amplified from S. thermophilus 
LMG18311 genomic DNA (American Type Culture Collection) and inserted into the 
pMAT expression vector (27,104). The resulting construct encodes Cas9 fused to an N-
terminal His6-MBP tag. Cas9 mutants were created using QuikChange site-directed 
mutagenesis method (Stratagene).  
To generate plasmid targets and RNA encoding vectors, synthetic 
oligonucleotides (100 nM), bearing the appropriate sequence, were annealed and ligated 
into either the pACYCDuet-1 (Novagen) or pMK-QR (GeneArt) using NcoI and EcoRI 
sites. Primers and oligonucleotides are listed in Table 1. All constructs were verified by 
DNA sequencing.   
 
Protein expression and purification 
Cas9 was overexpressed in T7Express E. coli (New England Biolabs). Cells were 
grown at 37°C in LB medium supplemented with Ampicillin to an A600 of ~0.3. Protein 
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expression was induced with 0.2 mM IPTG overnight at 20°C. Cells were harvested by 
centrifugation and quickly frozen in liquid nitrogen.  
For purification, cells were resuspended in lysis buffer (20 mM Tris-HCl pH 8.0, 
500 mM NaCl, 10 mM imidazole, and 10% glycerol) supplemented with protease 
inhibitor cocktail (Sigma Aldrich) and lysed by French press. Lysate was clarified by 
centrifugation at 18,000 rpm at 4 °C for 45 min, and the supernatant loaded on a 5 mL 
immobilized metal chromatography column (Bio-Rad) charged with nickel sulfate. The 
column was washed with lysis buffer, and bound protein eluted with lysis buffer 
containing 250 mM imidazole. The elution was run on a HiLoad 26/60 S200 size 
exclusion column (GE Healthcare) pre-equilibrated with gel-filtration buffer A (20 mM 
Tris-HCl pH 8.0, and 500 mM NaCl). Fractions containing His6-MBP tagged Cas9 were 
collected and treated with TEV protease overnight at 4°C to remove the His6-MBP tag.  
Samples were re-applied to immobilized metal affinity chromatography resin to remove 
the His-tagged TEV protease, free His6-MBP and any remaining tagged protein. The 
flow-through was collected, concentrated using an Ultracel 10K centrifugal filter unit 
(Millipore), and further purified by size exclusion chromatography in gel-filtration buffer 
B (20 mM Tris-HCl pH 8.0, 200 mM KCl, and 1 mM EDTA). The final fractions 
containing Cas9 were concentrated to ~16 mg/ml. Purified proteins were >95% pure as 
judged by SDS-PAGE and Coomassie staining (Fig 3.1A). The mutant variants of Cas9 
were expressed and purified in the same manner as the wild-type protein (Fig 3.1A).   
 
RNA preparation  
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RNAs were generated by in vitro transcription using T7 RNA polymerase. 
Plasmid templates were linearized overnight with EcoRI and then purified by 
phenol:chloroform extraction and ethanol precipitation. 0.5 ug of linear plasmid template 
was incubated with 0.1 mg/ml T7 RNA polymerase and 5 mM each of CTP, GTP, ATP, 
UTP in reaction buffer (25 mM Tris-HCl pH 8.0, 1.5 mM MgCl2, 2 mM spermidine, 40 
mM DTT) at 37 °C for 3 hours. RNA transcripts were then gel purified.  
 
In vivo transformation assay  
The recipient cells were prepared by co-transforming E. coli BL21 (DE3) with 
plasmids encoding Cas9 (pMAT) and sgRNA (pRSFDuet-1) or empty vectors. All 
plasmids, including the targets, had unique selection markers and origins of replication. 
The transformation assay was performed using the CaCl2 heat-shock procedure as 
described in Chapter 1 with minor changes. 1 ml of cells was used for each 
transformation assay, and each time cells were resuspended with 0.5 ml of “Na” or “Ca 
solution”. The final cells were resuspended in 50 µl of “Ca solution”, transformed with 5 
ng plasmid DNA, and recovered in LB medium containing 0.2 mM IPTG at 37 °C for 1 
hour and plated on LB agar containing appropriate antibiotics and 0.2 mM IPTG. 
Reported transformation efficiencies are the average of at least three biological replicates. 
All target plasmids used in this study transformed into control recipient cells with the 
same efficiency (~200 colony forming units per 5 ng DNA).  
  
Plasmid cleavage assay  
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Cas9 (25 nM), tracrRNA (25 nM) and crRNA (25 nM) were incubated in a 
cleavage buffer (20 mM HEPES pH 7.5, 150 mM KCl, 10 mM MgCl2) at 37 °C for 30 
minutes. The reactions were initiated by adding plasmid targets (4 nM), incubated at 37 
°C for 30 min and quenched with phenol. The aqueous layer was extracted and separated 
on a 0.8% agarose gel. Gels were stained by soaking in 1× TAE buffer supplemented 
with 5 ug/ul ethidium bromide for 1 hour, and then for a further hour in 1× TAE buffer. 
Bands were visualized using an FLA-7000 (Fuji) and quantified with ImageGauge (Fuji). 
To account for the different binding affinity of ethidium bromide to linear and 
supercoiled DNA, control samples with equal amounts of DNA in both forms were 
loaded on the same gel. The ratios of the fluorescence intensities of linear and 





where ILin and Isc are the intensities of the linear and supercoiled bands, respectively. In 
our case K was determined to be 0.4 ± 0.05 and did not vary significantly between 
experiments. The percentage of linear product was then calculated as follows (105):   




  ×  100 
 
Electrophoresis mobility shift assay  
DNA oligonucleotides were purified on 10% denaturing polyacrylamide gels. 
dsDNA targets (Table 3.1) were made by annealing each strand and purified on 12% 
native polyacrylamide gels containing 1× TBE.  dsDNA were 5’ end labeled with [γ-32P]-
ATP using T4 polynucleotide kinase (New England Biolabs). A fixed concentration (10-
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100 pM) of labeled dsDNA targets were mixed with an increasing concentration of pre-
mixed Cas9D9A,H599A-sgRNA complex. Binding assays, performed in buffer (20 mM 
HEPES pH 7.5, 150 mM KCl, 10 mM MgCl2, 0.1 mg/mL BSA, and 10% glycerol), were 
incubated at 37 °C for 30 min, followed by separation on 5% native polyacrylamide gels. 
Gels were visualized by phosphorimaging (Fuji) and quantified with ImageGauge (Fuji). 
Fraction DNA bound was plotted versus concentration of Cas9, and data fit to a one-site 
binding isotherm using GraphPad Prism software. Reported Kd values are the average of 














* John Choi, a ScM student (2012-2013), worked on in vivo transformation assay, determined correlation 
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Table 3. 1  Primer and oligonucleotides used in these studies 
 
  Sequence (5’ to 3’) 
 





Primers for site directed mutagenesis: 
D9A forward GTGACTTAGTTTTAGGACTTGCTATCGGTATAGGTTCTGTTG 
D9A Reverse CAACAGAACCTATACCGATAGCAAGTCCTAAAACTAAGTCAC 
H599A forward CCTAATCAGTTTGAAGTAGATGCTATTTTACCTCTTTCTATCAC 
H599A Reverse GTGATAGAAAGAGGTAAAATAGCATCTACTTCAAACTGATTAGG 
 
 







Oligonucleotides used as the template for in vitro transcription of sgRNA: 
S1 Forward GAAATTAATACGACTCACTATAGGCTACCCCGTATGTCAGAGAGGT 
 TTTTGTACTCTGAAAAATCTTGCAGAAGCTACAAAGATAAGGCTTC 
 ATGCCGAAATC 
S1 Reverse GATTTCGGCATGAAGCCTTATCTTTGTAGCTTCTGCAAGATTTTTCA 
                              GAGTACAAAAACCTCTCTGACATACGGGGTAGCCTATAGTGAGTC 
GTATTAATTTC 
S2 Forward GAAATTAATACGACTCACTATAGGTTACCTTGAAAAAAGGAACGG 
 TTTTTGTACTCTGAAAAATCTTGCAGAAGCTACAAAGATAAGGCTTC 
 ATGCCGAAATC 
S2 Reverse GATTTCGGCATGAAGCCTTATCTTTGTAGCTTCTGCAAGATTTTTCA 






tracrRNA  AAUCUUGCAGAAGCUACAAAGAUAAGGCUUCAUGCCGAAAUC  
 
 
Oligonucleotides used to construct the plasmid targets: 
S1 top strand:  CATGCATTTTGCAACTCTCTGACATACGGGGCAGCTGGTAGCTCA 
 TACTCATGA 
S1 bottom strand: AATTTCATGAGTATGAGCTACCAGCTGCCCCGTATGTCAGAGAGT 
 TGCAAAATG 
S2 top strand: CATGCATTTTGCAACGTTCCTTTTTTCAAGGTAATCTTTGAAAGA 
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 TACTCATGA 




Oligonucleotides used to construct synthetic DNA targets: 
Top strand: CATTTTGCAACTCTCTGACATACGGGGCAGCTGGTAGCTCATACTC 
ATGA 
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Final Conclusions 
CRISPR-Cas provides prokaryotes with adaptive and inheritable immunity 
against invasive genetic elements. This immunity is exerted through a three-stage 
pathway: adaptation, crRNA processing, and target interference. This thesis primarily 
focuses on the biochemical and structural aspects of the target interference stage of type I 
and type II systems. The studies presented here include in vitro and in vivo reconstitution 
of the two systems, characterization of protein-nucleic acid interactions and structural 
analysis of the protein complexes. These results contribute to the understanding of the 
molecular basis of the targeting mechanisms in type I and type II CRISPR-Cas systems.  
In Chapter 2, we explored a crucial step—R-loop formation—during target 
recognition by type I surveillance complex Cascade. Our lab previously solved a crystal 
structure of E. coli Cascade bound to crRNA and a ssDNA target, which provided 
important information about target binding by Cascade (23). In this study, we identified a 
binding pocket for the non-target DNA strand, and verified its function through 
mutational analysis. We showed via filter binding assay and magnetic tweezer 
experiments that mutations in this pocket impair R-loop formation, probably due to the 
weakened interactions with the non-target strand. However, these mutations do not affect 
the R-loop stability once R-loops are formed, suggested by magnetic tweezer experiments 
and Cas3 recruitment assay. In addition, in vivo plasmid transformation showed that cells 
harboring mutant Cascade have mild defects in eliminating a target plasmid. These 
results suggest that, besides stabilizing the target strand through base paring with crRNA 
and interactions with subunits (23), sequestering the non-target strand also contributes to 
the formation of an R-loop. However, the R-loop stability seems to be primarily 
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determined by the ability of Cascade to apply a conformational “lock” (72), which is 
likely accompanied by a concerted structural rearrangement in Cascade upon target 
binding (20,23).    
In Chapter 3, we characterized a Cas9 ortholog from S. thermophilus LMG18311. 
The purpose of this study was to expand current CRISPR-Cas9 genome engineering 
toolbox and increase the capacity of multiplex editing with different Cas9 orthologs. We 
demonstrated both in vivo and in vitro that LMG18311 Cas9 effectively cleaves dsDNA 
using either separated crRNA and tracrRNA or a chimeric sgRNA. The cleavage is 
dependent on sequence complementarity between crRNA and the target as well as the 
presence of a PAM motif. We identified the PAM as 5’-GCAAA-3’, with the first G 
being the most important. Furthermore, we showed that both the cleavage efficiency and 
cleavage position vary depending on the position of PAM. The HNH domain cleaves the 
target strand at a fixed position, whereas the RuvC-like domain cleaves the non-target 
strand using a ruler mechanism. The flexibility of the relative position of the two domains 
is supported by the structural studies of Cas9 (43-47).    
These studies, together with others, revealed a few similarities between the type I 
and type II systems. First of all, they both target dsDNA. Unlike type III systems, which 
cleave the non-template DNA strand and the RNA transcript in a transcription bubble 
(106-108), type I and II systems cleave dsDNA and this activity relies strictly on the 
DNA sequence, independent of transcription. Secondly, PAM is used in both systems to 
discriminate self versus “non-self” DNA elements. While in Type III systems cleavage is 
prevented by the presence of homology between crRNA and the 5’ flanking sequence of 
the target (32,108), in type I and II systems the recognition of PAM adjacent to the target 
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licenses DNA cleavage. However, the tolerance for PAM mutations appears to be 
relatively relaxed. For example, E. coli Cascade can use CTT, CTA, CCT, CTC, or CAT 
for target interference (25), and S. thermophilus LMG18311 Cas9 tolerates mutations at 
position 2 to 5 of its PAM 5’-GCAAA-3’. Thirdly, both Cascade and Cas9 carry out 
directional formation of R-loop between the crRNA and the dsDNA target. Both systems 
initiate the search by scanning for PAMs. After PAM recognition, a short segment in 
crRNA immediately after PAM, termed “seed” sequence, is used to nucleate an R-loop, 
which further expands to a complete R-loop across the homologous region (37,48,76,77). 
Single molecule experiments have provided direct evidence for directional R-loop 
formation by both Cascade and Cas9 (48,72,73). In our study, we showed that the R-loop 
expansion in Cascade is facilitated by sequestering the non-target strand in a distinct 
binding pocket.  
On the other hand, mechanistic differences are also observed between type I and 
II systems during target interference. First of all, a fundamental difference is the complex 
composition. Type I systems require a multimeric complex Cascade and Cas3 to 
complete target destruction, whereas type II systems only need a single large protein 
Cas9. Secondly, the RNA component in each complex differs greatly. Type I crRNA is 
generated by a one-step processing by Cas6 at repeat regions and thus contains an intact 
spacer sequence of 32-33 nt (16). In contrast, type II crRNA undergoes two processing 
events by RNase III and an unknown nuclease, and the resulted crRNA remains 
hybridized to tracrRNA at its 3’ end and contains only 20 nt spacer sequence at its 5’ end 
(36). In addition, the conformation of crRNA presented in the pre-target bound 
complexes is drastically different, which implies distinct mechanisms for target binding. 
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Interestingly, Cascade displays its entire spacer region as six discrete segments in a 
distorted A-form configuration (22,24), using a conformation proof-reading mechanism 
similar to that used by RecA (23), whereas Cas9 pre-organizes only its first 10 nt spacer 
sequence in A-form, using a “seed” mechanism	   reminiscent of that used by Argonaute 
proteins (46). Lastly, as for target cleavage, while type II Cas9 simply generates a blunt 
dsDNA break (37), type I systems involve a more complicated process. After R-loop 
formation by Cascade, Cas3 is recruited to the complex, first nicks the non-target strand 
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Future Directions 
Cas3 recruitment 
Although several structures of Cascade and Cas3 have been solved individually 
(see introduction), how the two interact is still unclear. Single-particle EM reveals that 
Cas3 colocalizes with Cse1 in Cascade, suggesting Cse1 likely provides a docking site 
for Cas3 (21). In fact, some systems encode a Cse1-Cas3 fusion protein, suggesting Cse1 
and Cas3 functions might be closely coupled (75). But the specific interactions are yet to 
be defined. In addition, targets with incorrect PAMs, even when R-loops are induced, can 
not activate Cas3-mediated cleavage (21,73). This implies that PAM verification is a 
prerequisite for Cas3 activation. Structural information of Cascade (specifically Cse1) 
bound to correct PAMs and mutated PAMs are needed to understand the mechanism of 
Cas3 activation.  
 
Priming 
 Cascade and Cas3 mediated interference machinery has been shown to be 
involved in “primed” spacer acquisition (13,14), as opposed to “naïve” acquisition where 
only Cas1 and Cas2 are needed. Primed spacer acquisition is driven by mutated targets 
that could otherwise escape the interference (13). However, the role of Cascade and Cas3 
in this process is poorly understood. Single-molecule FRET experiments revealed that 
Cascade distinguishes mutated targets from bona fide targets using a distinct low-fidelity 
binding mode (109).  Exactly how Cascade binds to a mutated target, for instance, 
containing PAM or seed mutations, has not been characterized. The canonical binding 
mode with bona fide targets is explained by a directional R-loop formation model. Under 
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this model, mismatches within PAM or seed sequence will lead to rejection of the target 
at an early stage. Thus, how does Cascade tolerate these escaping mutations in the primed 
binding mode? Furthermore, the primed binding mode does not lead to target cleavage 
(13). Another intriguing question is how Cascade signals Cas3 to carry out priming, but 
not to cleave the target. These questions require rigorous structural and biochemical 
studies.  
 
Customized PAM specifications 
When designing genome editing applications using Cas9, one needs to take into 
account the requirement of PAM adjacent to the desired target site. The most widely used 
S. pyogenes Cas9 recognizes a canonical NGG PAM. Although this sequence should 
appear in a genome quite frequently, it still puts constrains to applications that require 
high precision (110). Therefore, research endeavors have been undertaken to engineer 
Cas9 variants with customized PAM specifications. Initial attempts to alter PAM 
recognition in S. pyogenes Cas9 have reached some encouraging results (47,110). In a 
recent study, Kleinstiver et al. successfully generated two S. pyogenes Cas9 variants that 
recognize an NGA PAM, and showed that these variants exhibit robust editing of 
endogenous sites in zebrafish and human cells that are not targetable by wild-type S. 
pyogenes Cas9 (110). However, three point mutations were introduced in each case to 
obtain the phenotype, suggesting these alterations can be difficult to achieve. Thus, high-
throughput approaches are needed to screen for mutations that can lead to desired PAM 
specifications. Furthermore, owing to high sequence variation in the PAM recognition 
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domain (45), applying similar strategies to other Cas9 orthologs will require detailed 
structural characterization of the particular Cas9.  
 
Off-target effects 
One major concern regarding the use of Cas9 for genome engineering 
applications has been its off-target effects, which means that RNA guided Cas9 can 
induce mutations at sites that share sequence homology to the intended target site. In the 
case of S. pyogens Cas9, the guide RNA harbors a 20-nt guide sequence, and Cas9 
recognizes 2 additional nucleotides from PAM (NGG); so, if binding to a target is strictly 
based on the sequence, the length of 22-nt should match to unique targets in eukaryotic 
genomes, given that the probability is 4−22 × 2 (both DNA strands). However, it has been 
shown that Cas9 can tolerate up to five mismatches in the target sequence (111), greatly 
increasing its probability of off-target activities. Several approaches to improve the 
specificity of Cas9 mediated targeting have been described. One study showed that the 
use of synthetic guide RNA rather than guide RNA-encoding plasmids, separate crRNA 
and tracrRNA instead of a chimeric sgRNA, and addition of two guanine nucleotides to 
the 5’ end of the guide sequence effectively reduces off-target mutation frequencies 
(112). Another study demonstrated that truncating the 5’ end of guide sequence to 17 or 
18 nt decreases unwanted off-target mutations by 5,000-fold while maintaining same on-
target editing efficiency (113). In addition to improved RNA design, a Cas9 paired 
nickase strategy has been proposed, in which two Cas9 nickases (with one nuclease 
domain inactivated) are programmed to target adjacent sites and nick the opposite DNA 
strand instead of cutting both strands at one site. Although these approaches have made 
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great improvement in the targeting specificity, the underlying mechanism of Cas9 off-
target activities has not yet been understood. A better characterization of Cas9 mediated 
DNA targeting is required before this technology is expanded for broader use in research 
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Crystallization of E. coli Cascade bound to DNA targets 
Crystallization of ssDNA bound Cascade  
* This structure was previously solved by Sabin Mulepati (23). These crystals were used 
for DNA soaking experiments and as diffraction controls.  
Cascade proteins were purified using protocol detailed in Chapter 2 Methods. 
ssDNA bound crystals were prepared as described in Supplementary Materials in (23). 
Firstly, the dsDNA target was prepared by slow-annealing 230 µM of the target strand 
(5’-AATCAGACAGCCCACATGGCATTCCACTTATCACTGGCAT-3’) with 200 µM 
of a non-target strand (5’-GCCATGTGGGCTGTCTGATT-3’) in a buffer containing 20 
mM Tris-HCl pH 7.5, 100 mM NaCl and 0.5 mM of EDTA. The non-target strand was 
designed to be complementary to the 5’-region of the target strand (Fig A.1A). The 
dsDNA target (30 µM) was then incubated with 20 µM Cascade at 37 °C for 30 min in a 
buffer containing 20 mM Tris-HCl pH 8.0 and 200 mM NaCl before crystallization.  
ssDNA bound Cascade crystals were obtained with sitting-drop vapor diffusion 
method by mixing 2 µl of the dsDNA-Cascade mixture with 1 µl of a reservoir solution 
containing 0.08 M sodium cacodylate pH 5.0, 0.1 M calcium acetate, and 9-11% PEG 
8,000. Crystals appeared after 1 day and grew to full size within a week at 20 °C (Fig 
A.2A). Larger crystals (~ 500 µm x 300 µm x 300 µm) were obtained by micro-seeding.  
 
Soaking with non-target strand DNA  
Since the ssDNA-bound Cascade structure does not contain the non-target strand, 
we sought to soak the ssDNA-bound Cascade crystals with high concentrations of non-
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target strand DNA. Because the binding to non-target strand is not sequence specific, we 
designed DNA substrates consisting of poly(A) and poly(T) with various lengths (dTn 
(n= 6, 9, 12) and dAn (n= 6, 9, 12)).  
We followed a “low-salt” soaking method as published in (114) with minor 
modifications. Firstly, we grew ssDNA-bound Cascade crystals as described above. After 
a week, large crystals (≥ 250 µm x 150 µm x 150 µm) were transferred into a clean 
reservoir solution and gradually buffer-exchanged into a low salt solution consisting of 
20 mM HEPE pH 7.5, 30 mM sodium cacodylate pH 5.0, 10% PEG 8000, and 5 % each 
of glycerol, sucrose, PEG 400, and ethylene glycol. Stabilized crystals were then looped 
into a second drop of the same low salt solution containing 5 mM ssDNA. Crystals were 
left in this solution overnight to allow time for binding. Crystals were then looped and 
flash frozen in liquid nitrogen for data collection.  
 
Crystallization of Cascade bound to PAM-containing DNA 
We attempted to introduce a double-stranded PAM into the current Cascade 
crystal form by extending the 3’ end of the target strand such that the extended sequence 
could base pair with 5’-CAT-3’ to form a double-stranded PAM (Fig A.1B). We 
designed new target strands that could fold at the 3’ region as a stem-loop of various 
lengths (n=4,5,6 bps) (Fig A.1B). We annealed these new DNAs with the same non-
target strand and carried out crystallization identically as before. Only DNA with a 5 bp 
stem-loop gave crystals in the initial screen. We then proceeded with this DNA and 
conducted further optimization. However, despite various attempts at optimization 
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(altering buffer concentration, pH, drop ratio, etc.), the maximum crystals obtained were 
~ 200 µm x 100 µm x 100 µm (Fig A.2B). Micro-seeding did not improve the 
crystallization, either.  
 
Data collection 
Cascade crystals were gradually cryo-protected in 5% steps into a cryoprotectant 
(0.1 M sodium cacodylate pH 5.0, 0.1 M calcium acetate, 10 % PEG 8,000, and 5 % each 
of glycerol, sucrose, PEG 400, and ethylene glycol), and subsequently flash frozen in 
liquid nitrogen. For crystals soaked with ssDNA, the procedure is detailed above. 
Diffraction data were collected at Beamline 7-1, 11-1, and 12-2 of Stanford Synchrotron 
Radiation Lightsource.  
 
Results 
We had limited success with the attempts to soak in non-target DNA and to 
crystalize Cascade with a PAM-containing DNA. A Cascade crystal soaked with dT12 
diffracted to ~ 5 Å. However, fitting the ssDNA-bound Cascade into density revealed no 
extra density of another ssDNA, suggesting no binding of the provided non-target strand. 
Meanwhile, the crystals of Cascade bound to PAM-containing DNA only diffracted to ~ 
8 Å.  
 
Discussion 
For DNA soaking experiments, the reasons for the lack of success could be a) the 
binding of the non-target strand alone has very low affinity, and b) the crystallization 
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condition is not optimal for binding. Beloglazova et al. performed permanganate 
footprinting on dsDNA bound to in vitro packaged Cascade-crRNA complexes and 
showed no protection on the non-target strand upon Cascade binding (115). Although 
contradicting previous results (19,33), this result suggests that binding to the non-target 
strand can be transient, which could explain no detection of binding at even millimolar 
concentrations of DNA. The crystallization buffer contained 10% PEG8000, which is a 
common precipitant of DNA. In fact, precipitation of DNA was seen during preparation, 
and this suggests that actual DNA concentration was lower than expected.  
For crystallization of Cascade bound to PAM-containing DNA, we were unable to 
improve the diffraction of the obtained crystals at the time. The fact that the crystals had 
limited growth could be due to low stability of Cascade and the DNA containing a short 
stem-loop.  van Erp et al. recently showed that at least 12 additional bps on the 3’ side of 
the protospacer sequence are required for high affinity binding to Cascade (78). Thus, the 
short base-paired region may cause low affinity binding to Cascade. Additionally, the 3’ 
extension of the target DNA is positioned between Cas7.5 and Cas7.6 (78). Therefore, 















Fig A. 1 Schematic of DNA substrates used in the crystallization of Cascade bound 
to DNA targets. (A) DNA substrates used for crystallization of Cascade bound to 
ssDNA. (B) DNA substrates used for crystallization of Cascade bound to PAM-



























Fig A. 2 Crystals of E. coli Cascade bound to DNA targets. (A) Crystals of Cascade 
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Crystallization of S. thermophilus LMG18311 Cas9 
Crystallization of native crystal  
S. thermophilus LMG18311 Cas9 was purified (see Chapter 3. Methods) and 
concentrated to ~ 16 mg/ml in gel filtration buffer (20 mM Tris-HCl pH 8.0, 200 mM 
KCl, and 1 mM EDTA). Crystals of Cas9 were grown with hanging drop vapor diffusion 
method by mixing 1 µl of protein with 1 µl of a reservoir solution (H2O) at 20 °C. 
Crystals appear after ~ 2 days and grow to full size within a week. Crystal sizes were 
improved to ~ 800	  µm × 300 µm × 200	  µm with micro-seeding (Fig A.3A).  
 
Selenomethionine (SeMet)	  substituted protein purification and crystallization 
pMAT11 Cas9 construct was expressed in T7 Express Crystal E. coli cells (New 
England Biolabs), which are methionine auxotroph. Cells were grown overnight at 37 °C 
in ½ LB medium and ½ M9 minimum medium supplemented with 0.2 mg/ml ampicillin. 
The minimum medium was supplemented with 5 mg/L tryptophan and tyrosine, 50 mg/L 
each remaining amino acid other than methionine, and 1% (v/v) Kao and Michayluk 
Vitamin Solution (Sigma-Aldrich). The concentrated tryptophan/tyrosine stock was made 
in 200 mM HCl, whereas the other amino acids were dissolved in water. The next day, a 
10 mL overnight culture was used to inoculate 1 L of the same minimal media without 
LB supplemented with 50 mg/ml SeMet and 0.2 mg/ml ampicillin. 0.2 mM IPTG was 
added to induce protein expression at the beginning of the growth. Cells were grown at 
37 °C to an OD600 of 0.4~0.5, and continued to grow for 18 h at 20 °C. Cells were 
harvested by centrifugation and quickly frozen in liquid nitrogen. SeMet Cas9 was 
purified similarly as native Cas9 but with minor modifications. All buffers for SeMet 
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Cas9 purification contained 1 mM TCEP. In addition, lysis buffer contained 1M NaCl 
instead of 500 mM NaCl for a better removal of nucleic acid contamination.  
SeMet Cas9 crystals were grown in the identical crystallization condition as the 
native crystals. However, crystals grew to a limited size (~ 300	  µm × 150 µm × 100	  µm) 
with morphology different from native crystals (Fig A.3B). Attempts to improve the 
crystals by adding crystal seeds, salt (MgCl2, KCl), or reducing agent (β-ME, DTT, 
TCEP,	  and	  Tris(hydroxymethyl)phosphine) did not achieve much success.     
 
Heavy metal soaking 
Native crystals were first harvested in cryoprotectant containing 2 mM Tris-HCl 
pH 8.0, 10 mM KCl, and 35% glycerol. The crystals were then soaked in cryoprotectant 
supplemented with 100 µM ~ 1 mM heavy-metal compounds for various duration of time 
(Table A.1). Additionally, because mercury binding to cysteine residues may cause 
significant nonisomorphism (116), we generated two Cas9 mutants C329S and C1086S.  
Crystals of mutants were soaked primarily with mercury compounds for ~ 3 h (Table 
A.1).   
 
Data collection 
Crystals were gradually buffer-exchanged into a cryoprotectant containing 2 mM 
Tris-HCl pH 8.0, 10 mM KCl, and 35% glycerol, and flash frozen in liquid nitrogen. 
Diffraction data were collected at Beamline 7-1, 11-1, and 12-2 of Stanford Synchrotron 
Radiation Lightsource.  
 
	   104	  
Results 
Native crystals diffracted to 3.3 Å; SeMet derivative crystals diffracted to ~7 Å. 
Datasets obtained with heavy metal soaked crystals showed no detectable anomalous 
signal. The crystals were identified as belonging to space group I222, with one molecule 
per asymmetric unit. One unit cell is 82 × 174 × 270 Å3.	  However, the heavy atom 




We encountered several technical problems with this project. Firstly, Cas9 
crystals grew in low ionic conditions such as H2O. As a result, the crystals were sensitive 
to any additives such as buffering agent or salt, which largely limited the strategies to 
improve crystal growth. Secondly, the crystals diffracted poorly and the diffraction was 
highly anisotropic. Although we were able to improve crystal size and morphology, 
diffraction quality did not improve accordingly. The best dataset obtained so far was at 
3.3 Å. Thirdly, SeMet protein purification gave very poor yields, and the SeMet crystals 
were not easily reproducible. Fourthly, because of the high sensitivity, native crystals 
could only sustain submillimolar concentrations of heavy metal solution, which could 
explain the ineffective binding. But in general, crystals were more sensitive to inorganic 
compounds such as HgCl2 or (NH4)2HgCl2, and less sensitive to organic compounds such 
as thiomersal (C9H9HgNaO2S) or C2H5HgCl. Lastly, molecular replacement with two 
known Cas9 structures (4CMP and 4OGE) (43) at the time did not achieve much success 
due to low sequence identity. These published structures also lowered the priority of this 
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project.  
    To determine this structure, several strategies could be tried in the future: a) 
seek a different crystal form; b) further optimize SeMet protein prep (growth, expression, 
buffer, etc.) and SeMet crystals; c) perform more exhaustive molecular replacement 






    
 
Fig A. 3 Crystals of S. thermophilus LMG18311 Cas9. (A) Examples of native Cas9 
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Number Metal Compound 
1 Hg Mercury chloride 
2 Hg Mercury acetate 
3 Hg Mercury (III) potassium iodide 
4 Hg Mercury ammonium chloride 
5 Hg Ethyl mercuric chloride 
6 Hg 4-(chloromercuri) benzene-sulfonic acid 
7 Hg 4-chloromercuribenzoic acid 
8 Hg Thimerosal 
9 Pt cis-Platinum(II) diammine dichloride 
10 Pt Potassium hexabromo platinate (IV) 
11 W Sodium tungstate 
12 W Paratungstate cluster 
13 Ta Tantalum cluster 
14 Sm Samarium (III) chloride 
15 Eu Europium (III) chloride 
16 Yb Ytterbium (III) chloride 
17 Ho Holmium (III) chloride 
18 Ho Holmium (III) acetate 
19 Er Erbium(III) chloride 
20 I “Magic Triangle” I3C 
	   108	  
References 
 
1. Bergh O, Børsheim KY, Bratbak G, Heldal M. High abundance of viruses found 
in aquatic environments. Nature. Nature Publishing Group; 1989 Aug 
10;340(6233):467–8.  
2. Samson JE, Magadán AH, Sabri M, Moineau S. Revenge of the phages: 
defeating bacterial defences. Nat Rev Microbiol. 2013 Oct;11(10):675–87.  
3. Mojica FJM, Díez-Villaseñor C, García-Martínez J, Soria E. Intervening 
sequences of regularly spaced prokaryotic repeats derive from foreign genetic 
elements. J Mol Evol. Springer-Verlag; 2005 Feb;60(2):174–82.  
4. Bolotin A, Quinquis B, Sorokin A, Ehrlich SD. Clustered regularly interspaced 
short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin. 
Microbiology (Reading, Engl). Microbiology Society; 2005 Aug;151(Pt 
8):2551–61.  
5. Pourcel C, Salvignol G, Vergnaud G. CRISPR elements in Yersinia pestis 
acquire new repeats by preferential uptake of bacteriophage DNA, and provide 
additional tools for evolutionary studies. Microbiology (Reading, Engl). 
Microbiology Society; 2005 Mar;151(Pt 3):653–63.  
6. Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, et al. 
CRISPR provides acquired resistance against viruses in prokaryotes. Science. 
American Association for the Advancement of Science; 2007 Mar 
23;315(5819):1709–12.  
7. Garneau JE, Dupuis M-È, Villion M, Romero DA, Barrangou R, Boyaval P, et 
al. The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid 
DNA. Nature. 2010 Nov 4;468(7320):67–71.  
8. Makarova KS, Wolf YI, Alkhnbashi OS, Costa F, Shah SA, Saunders SJ, et al. 
An updated evolutionary classification of CRISPR-Cas systems. Nat Rev 
Microbiol. Nature Publishing Group; 2015 Sep 28.  
9. van der Oost J, Westra ER, Jackson RN, Wiedenheft B. Unravelling the 
structural and mechanistic basis of CRISPR-Cas systems. Nat Rev Microbiol. 
Nature Publishing Group; 2014 Jul;12(7):479–92.  
10. Makarova KS, Haft DH, Barrangou R, Brouns SJJ, Charpentier E, Horvath P, et 
al. Evolution and classification of the CRISPR-Cas systems. Nat Rev Microbiol. 
2011 Jun;9(6):467–77.  
11. Nuñez JK, Lee ASY, Engelman A, Doudna JA. Integrase-mediated spacer 
acquisition during CRISPR-Cas adaptive immunity. Nature. 2015 Mar 
	   109	  
12;519(7542):193–8.  
12. Wang J, Li J, Zhao H, Sheng G, Wang M, Yin M, et al. Structural and 
Mechanistic Basis of PAM-Dependent Spacer Acquisition in CRISPR-Cas 
Systems. Cell. Elsevier Inc; 2015 Oct 14;:1–15.  
13. Datsenko KA, Pougach K, Tikhonov A, Wanner BL, Severinov K, Semenova E. 
Molecular memory of prior infections activates the CRISPR/Cas adaptive 
bacterial immunity system. Nat Comms. 2012 Jul 10;3:945.  
14. Swarts DC, Mosterd C, van Passel MWJ, Brouns SJJ. CRISPR interference 
directs strand specific spacer acquisition. PLoS ONE. Public Library of Science; 
2012;7(4):e35888.  
15. Fineran PC, Charpentier E. Memory of viral infections by CRISPR-Cas adaptive 
immune systems: acquisition of new information. Virology. 2012 Dec 
20;434(2):202–9.  
16. Brouns SJJ, Jore MM, Lundgren M, Westra ER, Slijkhuis RJH, Snijders APL, et 
al. Small CRISPR RNAs guide antiviral defense in prokaryotes. Science. 
American Association for the Advancement of Science; 2008 Aug 
15;321(5891):960–4.  
17. Gesner EM, Schellenberg MJ, Garside EL, George MM, MacMillan AM. 
Recognition and maturation of effector RNAs in a CRISPR interference 
pathway. Nature Publishing Group. Nature Publishing Group; 2011 May 
15;18(6):688–92.  
18. Sashital DG, Jinek M, Doudna JA. An RNA-induced conformational change 
required for CRISPR RNA cleavage by the endoribonuclease Cse3. Nature 
Publishing Group. Nature Publishing Group; 2011 May 15;18(6):680–7.  
19. Jore MM, Lundgren M, van Duijn E, Bultema JB, Westra ER, Waghmare SP, et 
al. Structural basis for CRISPR RNA-guided DNA recognition by Cascade 2011. 
Nature Publishing Group. Nature Publishing Group; 2011 Apr 3;18(5):529–36.  
20. Wiedenheft B, Lander GC, Zhou K, Jore MM, Brouns SJJ, van der Oost J, et al. 
Structures of the RNA-guided surveillance complex from a bacterial immune 
system. Nature. Nature Publishing Group; 2012 Apr 12;477(7365):486–9.  
21. Hochstrasser ML, Taylor DW, Bhat P, Guegler CK, Sternberg SH, Nogales E, et 
al. CasA mediates Cas3-catalyzed target degradation during CRISPR RNA-
guided interference. Proc Natl Acad Sci USA. National Acad Sciences; 2014 
May 6;111(18):6618–23.  
22. Jackson RN, Golden SM, van Erp PBG, Carter J, Westra ER, Brouns SJJ, et al. 
Structural biology. Crystal structure of the CRISPR RNA-guided surveillance 
complex from Escherichia coli. Science. American Association for the 
	   110	  
Advancement of Science; 2014 Sep 19;345(6203):1473–9.  
23. Mulepati S, Héroux A, Bailey S. Structural biology. Crystal structure of a 
CRISPR RNA-guided surveillance complex bound to a ssDNA target. Science. 
American Association for the Advancement of Science; 2014 Sep 
19;345(6203):1479–84.  
24. Zhao H, Sheng G, Wang J, Wang M, Bunkoczi G, Gong W, et al. Crystal 
structure of the RNA-guided immune surveillance Cascade complex in 
Escherichia coli. Nature. Nature Publishing Group; 2014 Nov 6;515(7525):147–
50.  
25. Fineran PC, Gerritzen MJH, Suárez-Diez M, Künne T, Boekhorst J, van Hijum 
SAFT, et al. Degenerate target sites mediate rapid primed CRISPR adaptation. 
Proc Natl Acad Sci USA. National Acad Sciences; 2014 Apr 22;111(16):E1629–
38.  
26. Sinkunas T, Gasiunas G, Fremaux C, Barrangou R, Horvath P, Siksnys V. Cas3 
is a single-stranded DNA nuclease and ATP-dependent helicase in the 
CRISPR/Cas immune system. The EMBO Journal. Nature Publishing Group; 
2011 Feb 22;30(7):1335–42.  
27. Mulepati S, Bailey S. In Vitro Reconstitution of an Escherichia coli RNA-guided 
Immune System Reveals Unidirectional, ATP-dependent Degradation of DNA 
Target. Journal of Biological Chemistry. 2013 Aug 2;288(31):22184–92.  
28. Mulepati S, Bailey S. Structural and Biochemical Analysis of Nuclease Domain 
of Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-
associated Protein 3 (Cas3). Journal of Biological Chemistry. 2011 Sep 
2;286(36):31896–903.  
29. Gong B, Shin M, Sun J, Jung C-H, Bolt EL, van der Oost J, et al. Molecular 
insights into DNA interference by CRISPR-associated nuclease-helicase Cas3. 
Proc Natl Acad Sci USA. National Acad Sciences; 2014 Nov 18;111(46):16359–
64.  
30. Huo Y, Nam KH, Ding F, Lee H, Wu L, Xiao Y, et al. Structures of CRISPR 
Cas3 offer mechanistic insights into Cascade-activated DNA unwinding and 
degradation. Nature Publishing Group. Nature Publishing Group; 2014 
Sep;21(9):771–7.  
31. Mojica FJM, Díez-Villaseñor C, García-Martínez J, Almendros C. Short motif 
sequences determine the targets of the prokaryotic CRISPR defence system. 
Microbiology (Reading, Engl). 2009 Mar;155(Pt 3):733–40.  
32. Marraffini LA, Sontheimer EJ. Self versus non-self discrimination during 
CRISPR RNA-directed immunity. Nature. 2010 Jan 28;463(7280):568–71.  
	   111	  
33. Sashital DG, Wiedenheft B, Doudna JA. Mechanism of foreign DNA selection in 
a bacterial adaptive immune system. Molecular Cell. 2012 Jun 8;46(5):606–15.  
34. Heler R, Samai P, Modell JW, Weiner C, Goldberg GW, Bikard D, et al. Cas9 
specifies functional viral targets during CRISPR-Cas adaptation. Nature. 2015 
Mar 12;519(7542):199–202.  
35. Wei Y, Terns RM, Terns MP. Cas9 function and host genome sampling in Type 
II-A CRISPR-Cas adaptation. Genes Dev. Cold Spring Harbor Lab; 2015 Feb 
15;29(4):356–61.  
36. Deltcheva E, Chylinski K, Sharma CM, Gonzales K, Chao Y, Pirzada ZA, et al. 
CRISPR RNA maturation by trans-encoded small RNA and host factor RNase 
III. 2011 Mar 31;471(7340):602–7. Available from: 
http://www.nature.com/doifinder/10.1038/nature09886 
37. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A 
Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial 
Immunity. 2012 Aug 16;337(6096):816–21. Available from: 
http://www.sciencemag.org/cgi/doi/10.1126/science.1225829 
38. Gasiunas G, Barrangou R, Horvath P, Siksnys V. Cas9-crRNA ribonucleoprotein 
complex mediates specific DNA cleavage for adaptive immunity in bacteria. 
Proc Natl Acad Sci USA. National Acad Sciences; 2012 Sep 25;109(39):E2579–
86.  
39. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex Genome 
Engineering Using CRISPR/Cas Systems. Science. 2013 Feb 14;339(6121):819–
23.  
40. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, et al. RNA-guided 
human genome engineering via Cas9. Science. American Association for the 
Advancement of Science; 2013 Feb 15;339(6121):823–6.  
41. Jinek M, East A, Cheng A, Lin S, Ma E, Doudna J. RNA-programmed genome 
editing in human cells. Elife. 2013;2:e00471.  
42. Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, et al. 
Repurposing CRISPR as an RNA-Guided Platform for Sequence-SpecificControl 
of Gene Expression. Cell. Elsevier; 2013 Feb 28;152(5):1173–83.  
43. Jinek M, Jiang F, Taylor DW, Sternberg SH, Kaya E, Ma E, et al. Structures of 
Cas9 endonucleases reveal RNA-mediated conformational activation. Science. 
2014 Mar 14;343(6176):1247997–7.  
44. Nishimasu H, Ran FA, Hsu PD, Konermann S, Shehata SI, Dohmae N, et al. 
Crystal Structure of Cas9in Complex with Guide RNA and Target DNA. Cell. 
Elsevier Inc; 2014 Feb 27;156(5):935–49.  
	   112	  
45. Nishimasu H, Cong L, Yan WX, Ran FA, Zetsche B, Li Y, et al. Crystal 
Structure of Staphylococcus aureus Cas9. Cell. 2015 Aug 27;162(5):1113–26.  
46. Jiang F, Zhou K, Ma L, Gressel S, Doudna JA. A Cas9–guide RNA complex 
preorganized for target DNA recognition. Science. American Association for the 
Advancement of Science; 2015 Jun 26;348(6242):1477–81.  
47. Anders C, Niewoehner O, Duerst A, Jinek M. Structural basis of PAM-
dependent target DNA recognition by the Cas9 endonuclease. Nature. Nature 
Publishing Group; 2014 Sep 16;513(7519):569–73.  
48. Sternberg SH, Redding S, Jinek M, Greene EC, Doudna JA. DNA interrogation 
by the CRISPR RNA-guided endonuclease Cas9. Nature. 2014 Mar 
6;507(7490):62–7.  
49. Pennisi E. The CRISPR craze. Science. American Association for the 
Advancement of Science; 2013 Aug 23;:833–6.  
50. Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 
for genome engineering. Cell. 2014 Jun 5;157(6):1262–78.  
51. Charpentier E, Marraffini LA. Harnessing CRISPR-Cas9 immunity for genetic 
engineering. Curr Opin Microbiol. 2014 Jun;19:114–9.  
52. Shariat N, Dudley EG. CRISPRs: molecular signatures used for pathogen 
subtyping. Appl Environ Microbiol. American Society for Microbiology; 2014 
Jan;80(2):430–9.  
53. Horvath P, Romero DA, Coute-Monvoisin AC, Richards M, Deveau H, Moineau 
S, et al. Diversity, Activity, and Evolution of CRISPR Loci in Streptococcus 
thermophilus. Journal of Bacteriology. 2008 Jan 29;190(4):1401–12.  
54. Fabre L, Zhang J, Guigon G, Le Hello S, Guibert V, Accou-Demartin M, et al. 
CRISPR typing and subtyping for improved laboratory surveillance of 
Salmonella infections. Mokrousov I, editor. PLoS ONE. Public Library of 
Science; 2012;7(5):e36995.  
55. Liu F, Barrangou R, Gerner-Smidt P, Ribot EM, Knabel SJ, Dudley EG. Novel 
virulence gene and clustered regularly interspaced short palindromic repeat 
(CRISPR) multilocus sequence typing scheme for subtyping of the major 
serovars of Salmonella enterica subsp. enterica. Appl Environ Microbiol. 
American Society for Microbiology; 2011 Mar;77(6):1946–56.  
56. Shariat N, DiMarzio MJ, Yin S, Dettinger L, Sandt CH, Lute JR, et al. The 
combination of CRISPR-MVLST and PFGE provides increased discriminatory 
power for differentiating human clinical isolates of Salmonella enterica subsp. 
enterica serovar Enteritidis. Food Microbiol. 2013 May;34(1):164–73.  
	   113	  
57. Bikard D, Hatoum-Aslan A, Mucida D, Marraffini LA. CRISPR interference can 
prevent natural transformation and virulence acquisition during in vivo bacterial 
infection. Cell Host Microbe. 2012 Aug 16;12(2):177–86.  
58. Hatoum-Aslan A, Marraffini LA. Impact of CRISPR immunity on the emergence 
and virulence of bacterial pathogens. Curr Opin Microbiol. 2014 Feb;17:82–90.  
59. Marraffini LA, Sontheimer EJ. CRISPR interference limits horizontal gene 
transfer in staphylococci by targeting DNA. Science. American Association for 
the Advancement of Science; 2008 Dec 19;322(5909):1843–5.  
60. Palmer KL, Gilmore MS. Multidrug-resistant enterococci lack CRISPR-cas. 
MBio. American Society for Microbiology; 2010;1(4):e00227–10.  
61. Marraffini LA. CRISPR-Cas immunity against phages: its effects on the 
evolution and survival of bacterial pathogens. Heitman J, editor. PLoS Pathog. 
Public Library of Science; 2013;9(12):e1003765.  
62. Luo ML, Leenay RT, Beisel CL. Current and future prospects for CRISPR-based 
tools in bacteria. Biotechnol Bioeng. 2015 Oct 13.  
63. Bikard D, Euler CW, Jiang W, Nussenzweig PM, Goldberg GW, Duportet X, et 
al. Exploiting CRISPR-Cas nucleases to produce sequence-specific 
antimicrobials. Nat Biotechnol. 2014 Nov;32(11):1146–50.  
64. Citorik RJ, Mimee M, Lu TK. Sequence-specific antimicrobials using efficiently 
delivered RNA-guided nucleases. Nat Biotechnol. 2014 Nov;32(11):1141–5.  
65. Schiffer JT, Aubert M, Weber ND, Mintzer E, Stone D, Jerome KR. Targeted 
DNA mutagenesis for the cure of chronic viral infections. J Virol. American 
Society for Microbiology; 2012 Sep;86(17):8920–36.  
66. Kennedy EM, Cullen BR. Bacterial CRISPR/Cas DNA endonucleases: A 
revolutionary technology that could dramatically impact viral research and 
treatment. Virology. 2015 May;479-480:213–20.  
67. Ebina H, Misawa N, Kanemura Y, Koyanagi Y. Harnessing the CRISPR/Cas9 
system to disrupt latent HIV-1 provirus. Sci Rep. 2013 Aug 26;3.  
68. Hu W, Kaminski R, Yang F, Zhang Y, Cosentino L, Li F, et al. RNA-directed 
gene editing specifically eradicates latent and prevents new HIV-1 infection. 
Proc Natl Acad Sci USA. National Acad Sciences; 2014 Aug 5;111(31):11461–
6.  
69. Xiao-Jie L, Hui-Ying X, Zun-Ping K, Jin-Lian C, Li-Juan J. CRISPR-Cas9: a 
new and promising player in gene therapy. J Med Genet. BMJ Publishing Group 
Ltd; 2015 May;52(5):289–96.  
	   114	  
70. Xue W, Chen S, Yin H, Tammela T, Papagiannakopoulos T, Joshi NS, et al. 
CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature. 
Nature Publishing Group; 2014 Oct 16;514(7522):380–4.  
71. Sinkunas T, Gasiunas G, Waghmare SP, Dickman MJ, Barrangou R, Horvath P, 
et al. In vitro reconstitution of Cascade-mediated CRISPR immunity in 
Streptococcus thermophilus. The EMBO Journal. 2013 Feb 6;32(3):385–94.  
72. Szczelkun MD, Tikhomirova MS, Sinkunas T, Gasiunas G, Karvelis T, Pschera 
P, et al. Direct observation of R-loop formation by single RNA-guided Cas9 and 
Cascade effector complexes. Proc Natl Acad Sci USA. National Acad Sciences; 
2014 Jul 8;111(27):9798–803.  
73. Rutkauskas M, Sinkunas T, Songailiene I, Tikhomirova MS, Siksnys V, Seidel 
R. Directional R-Loop Formation by the CRISPR-Cas Surveillance Complex 
Cascade Provides Efficient Off-Target Site Rejection. Cell Rep. 2015 Mar 3.  
74. Mulepati S, Orr A, Bailey S. Crystal Structure of the Largest Subunit of a 
Bacterial RNA-guided Immune Complex and Its Role in DNA Target Binding. 
Journal of Biological Chemistry. 2012 Jun 29;287(27):22445–9.  
75. Westra ER, van Erp PBG, Künne T, Wong SP, Staals RHJ, Seegers CLC, et al. 
CRISPR immunity relies on the consecutive binding and degradation of 
negatively supercoiled invader DNA by Cascade and Cas3. Molecular Cell. 2012 
Jun 8;46(5):595–605.  
76. Wiedenheft B, van Duijn E, Bultema JB, Waghmare SP, Zhou K, Barendregt A, 
et al. RNA-guided complex from a bacterial immune system enhances target 
recognition through seed sequence interactions. Proceedings of the National 
Academy of Sciences. National Acad Sciences; 2011 Jun 21;108(25):10092–7.  
77. Semenova E, Jore MM, Datsenko KA, Semenova A, Westra ER, Wanner B, et 
al. Interference by clustered regularly interspaced short palindromic repeat 
(CRISPR) RNA is governed by a seed sequence. Proc Natl Acad Sci USA. 
National Acad Sciences; 2011 Jun 21;108(25):10098–103.  
78. van Erp PBG, Jackson RN, Carter J, Golden SM, Bailey S, Wiedenheft B. 
Mechanism of CRISPR-RNA guided recognition of DNA targets in Escherichia 
coli. Nucleic Acids Research. 2015 Aug 3;:gkv793.  
79. Ban C, Junop M, Yang W. Transformation of MutL by ATP binding and 
hydrolysis: a switch in DNA mismatch repair. Cell. 1999 Apr 2;97(1):85–97.  
80. Shen B, Zhang J, Wu H, Wang J, Ma K, Li Z, et al. Generation of gene-modified 
mice via Cas9/RNA-mediated gene targeting. Cell Res. Nature Publishing 
Group; 2013 May;23(5):720–3.  
81. Wang H, Yang H, Shivalila CS, Dawlaty MM, Cheng AW, Zhang F, et al. One-
	   115	  
step generation of mice carrying mutations in multiple genes by CRISPR/Cas-
mediated genome engineering. Cell. 2013 May 9;153(4):910–8.  
82. Cho SW, Kim S, Kim JM, Kim J-S. Targeted genome engineering in human cells 
with the Cas9 RNA-guided endonuclease. Nat Biotechnol. Nature Publishing 
Group; 2013 Mar;31(3):230–2.  
83. Li J-F, Norville JE, Aach J, McCormack M, Zhang D, Bush J, et al. Multiplex 
and homologous recombination-mediated genome editing in Arabidopsis and 
Nicotiana benthamiana using guide RNA and Cas9. Nat Biotechnol. Nature 
Publishing Group; 2013 Aug;31(8):688–91.  
84. Nekrasov V, Staskawicz B, Weigel D, Jones JDG, Kamoun S. Targeted 
mutagenesis in the model plant Nicotiana benthamiana using Cas9 RNA-guided 
endonuclease. Nat Biotechnol. Nature Publishing Group; 2013 Aug;31(8):691–3.  
85. Gratz SJ, Cummings AM, Nguyen JN, Hamm DC, Donohue LK, Harrison MM, 
et al. Genome engineering of Drosophila with the CRISPR RNA-guided Cas9 
nuclease. Genetics. Genetics Society of America; 2013 Aug;194(4):1029–35.  
86. Friedland AE, Tzur YB, Esvelt KM, Colaiácovo MP, Church GM, Calarco JA. 
Heritable genome editing in C. elegans via a CRISPR-Cas9 system. Nat Meth. 
Nature Publishing Group; 2013 Aug;10(8):741–3.  
87. DiCarlo JE, Norville JE, Mali P, Rios X, Aach J, Church GM. Genome 
engineering in Saccharomyces cerevisiae using CRISPR-Cas systems. Nucleic 
Acids Research. Oxford University Press; 2013 Apr;41(7):4336–43.  
88. Jiang W, Bikard D, Cox D, Zhang F, Marraffini LA. RNA-guided editing of 
bacterial genomes using CRISPR-Cas systems. Nat Biotechnol. Nature 
Publishing Group; 2013 Mar;31(3):233–9.  
89. Nakayama T, Fish MB, Fisher M, Oomen Hajagos J, Thomsen GH, Grainger 
RM. Simple and efficient CRISPR/Cas9-mediated targeted mutagenesis in 
Xenopus tropicalis. genesis. 2013 Dec 1;51(12):835–43.  
90. Hwang WY, Fu Y, Reyon D, Maeder ML, Tsai SQ, Sander JD, et al. Efficient 
genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol. Nature 
Publishing Group; 2013 Mar;31(3):227–9.  
91. Bikard D, Jiang W, Samai P, Hochschild A, Zhang F, Marraffini LA. 
Programmable repression and activation of bacterial gene expression using an 
engineered CRISPR-Cas system. Nucleic Acids Research. Oxford University 
Press; 2013 Aug;41(15):7429–37.  
92. Maeder ML, Linder SJ, Cascio VM, Fu Y, Ho QH, Joung JK. CRISPR RNA-
guided activation of endogenous human genes. Nat Meth. Nature Publishing 
	   116	  
Group; 2013 Oct;10(10):977–9.  
93. Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE, et al. CRISPR-
mediated modular RNA-guided regulation of transcription in eukaryotes. Cell. 
2013 Jul 18;154(2):442–51.  
94. Shah SA, Erdmann S, Mojica FJM, Garrett RA. Protospacer recognition motifs: 
mixed identities and functional diversity. rnabiology. Taylor & Francis; 2013 
May;10(5):891–9.  
95. Deveau H, Barrangou R, Garneau JE, Labonte J, Fremaux C, Boyaval P, et al. 
Phage Response to CRISPR-Encoded Resistance in Streptococcus thermophilus. 
Journal of Bacteriology. 2008 Jan 29;190(4):1390–400.  
96. Zhang Y, Heidrich N, Ampattu BJ, Gunderson CW, Seifert HS, Schoen C, et al. 
Processing-Independent CRISPR RNAs Limit Natural Transformation in 
Neisseria meningitidis. Molecular Cell. Elsevier Inc; 2013 May 23;50(4):488–
503.  
97. Mali P, Esvelt KM, Church GM. Cas9 as a versatile tool for engineering biology. 
Nat Meth. 2013 Sep 27;10(10):957–63.  
98. Esvelt KM, Mali P, Braff JL, Moosburner M, Yaung SJ, Church GM. Orthogonal 
Cas9 proteins for RNA-guided gene regulation and editing. Nat Meth. 2013 Sep 
29;10(11):1116–21.  
99. Sapranauskas R, Gasiunas G, Fremaux C, Barrangou R, Horvath P, Siksnys V. 
The Streptococcus thermophilus CRISPR/Cas system provides immunity in 
Escherichia coli. Nucleic Acids Research. 2011 Nov 23;39(21):9275–82.  
100. Karvelis T, Gasiunas G, Miksys A, Barrangou R, Horvath P, Siksnys V. crRNA 
and tracrRNA guide Cas9-mediated DNA interference in Streptococcus 
thermophilus. rnabiology. Taylor & Francis; 2013 May;10(5):841–51.  
101. Magadán AH, Dupuis M-È, Villion M, Moineau S. Cleavage of Phage DNA by 
the Streptococcus thermophilus CRISPR3-Cas System. Poteete AR, editor. PLoS 
ONE. Public Library of Science; 2012 Jul 20;7(7):e40913.  
102. Cho SW, Kim S, Kim JM, Kim J-S. Targeted genome engineering in human cells 
with the Cas9 RNA-guided endonuclease. Nat Biotechnol. Nature Publishing 
Group; 2013 Jan 29;31(3):230–2.  
103. Hsu PD, Scott DA, Weinstein JA, Ran FA, Konermann S, Agarwala V, et al. 
DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol. 
Nature Publishing Group; 2013 Sep;31(9):827–32.  
104. Peränen J, Rikkonen M, Hyvönen M, Kääriäinen L. T7 vectors with modified 
T7lac promoter for expression of proteins in Escherichia coli. Anal Biochem. 
	   117	  
1996 May 1;236(2):371–3.  
105. Panyutin IV, Luu AN, Panyutin IG, Neumann RD. Strand breaks in whole 
plasmid dna produced by the decay of (125)I in a triplex-forming 
oligonucleotide. Radiat Res. 2001 Aug;156(2):158–66.  
106. Deng L, Garrett RA, Shah SA, Peng X, She Q. A novel interference mechanism 
by a type IIIB CRISPR-Cmr module in Sulfolobus. Molecular Microbiology. 
2013 Mar;87(5):1088–99.  
107. Goldberg GW, Jiang W, Bikard D, Marraffini LA. Conditional tolerance of 
temperate phages via transcription-dependent CRISPR-Cas targeting. Nature. 
2014 Oct 30;514(7524):633–7.  
108. Samai P, Pyenson N, Jiang W, Goldberg GW, Hatoum-Aslan A, Marraffini LA. 
Co-transcriptional DNA and RNA Cleavage during Type III CRISPR-Cas 
Immunity. Cell. 2015 May 21;161(5):1164–74.  
109. Blosser TR, Loeff L, Westra ER, Vlot M, Künne T, Sobota M, et al. Two distinct 
DNA binding modes guide dual roles of a CRISPR-Cas protein complex. 
Molecular Cell. 2015 Apr 2;58(1):60–70.  
110. Kleinstiver BP, Prew MS, Tsai SQ, Topkar VV, Nguyen NT, Zheng Z, et al. 
Engineered CRISPR-Cas9 nucleases with altered PAM specificities. Nature. 
Nature Publishing Group; 2015 Jul 23;523(7561):481–5.  
111. Fu Y, Foden JA, Khayter C, Maeder ML, Reyon D, Joung JK, et al. High-
frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human 
cells. Nat Biotechnol. Nature Publishing Group; 2013 Sep;31(9):822–6.  
112. Cho SW, Kim S, Kim Y, Kweon J, Kim HS, Bae S, et al. Analysis of off-target 
effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. 
Genome Res. Cold Spring Harbor Lab; 2014 Jan;24(1):132–41.  
113. Fu Y, Sander JD, Reyon D, Cascio VM, Joung JK. Improving CRISPR-Cas 
nuclease specificity using truncated guide RNAs. Nat Biotechnol. 2014 
Mar;32(3):279–84.  
114. Duderstadt KE, Chuang K, Berger JM. DNA stretching by bacterial initiators 
promotes replication origin opening. Nature. Nature Publishing Group; 2011 Oct 
13;478(7368):209–13.  
115. Beloglazova N, Kuznedelov K, Flick R, Datsenko KA, Brown G, Popovic A, et 
al. CRISPR RNA binding and DNA target recognition by purified Cascade 
complexes from Escherichia coli. Nucleic Acids Research. Oxford University 
Press; 2015 Jan 9;43(1):530–43.  
116. Cook WJ, Jeffrey LC, Sullivan ML, Vierstra RD. Three-dimensional structure of 
	   118	  












































	   119	  
Hongfan Chen 
                                                                                                                              DOB Dec 27, 1987 





2010 – present  
 



























Chen, H., Rouillon, C., Kaila, J., Mallon, J., Seidel, R., Bailey, S.. Mechanistic insights into R-
loop formation by the E. coli surveillance complex Cascade. In preparation 
 
Chen, H., Choi, J., Bailey, S.. Cut site selection by the two nuclease domains of the Cas9 RNA-
guided endonuclease. J Biol Chem. 2014 May 9;289(19):13284-94. 
 
Zhang, H., Chen, H., An, Y., Wang, H., Duan, W.. Evaluation on methods of human nuclear 
DNA extraction from free margins of finger nail and hair samples. Chinese Journal of Evidence 




Ph.D. candidate, Biochemistry & Molecular Biology, expected Jan 2016 
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA  
 
B.S., Biotechnology 
Fudan University, Shanghai, China 
 
Attendee 
Harvard Summer School, Shanghai, China 
Exchange student 
University of Hong Kong, Hong Kong, China 
Research Assistant, Johns Hopkins Bloomberg School of Public Health 
Department of Biochemistry & Molecular Biology, PI: Scott Bailey 
Project: Biochemical and structural characterization of RNA-guided DNA 
targeting CRISPR/Cas systems in bacteria.  
 
Research Assistant, Fudan University 
Center for Biotechnology, PI: Chunhua Yin 
Project: Synthesis and characterization of chitosan-derivative nanoparticles as 
anti-tumor drug delivery platforms.  
 
Undergraduate Researcher, Fudan University 
Institute of Genetics, PI: Hongyan Wang 
Project:  Evaluation of methods for human nuclear DNA extraction from free 
margins of finger nail and hair samples. 
	   120	  
PRESENTATIONS 
 
Chen, H., Rouillon, C., Seidel, R., Bailey, S. Insights into R-loop formation by E. coli Cascade. 
Poster presentation, CRISPR Conference 2015, New York, NY 
 
Chen, H., Bailey, S. Structure-function studies Structure-function Studies of E. coli RNA-guided 
surveillance complex Cascade. Oral presentation, JHSPH BMB Annual Retreat 2015, Baltimore, 
MD 
 
Chen, H., Choi, J., Bailey, S. Cleavage site selection by Cas9 nuclease domains. Poster 
presentation, JHSPH BMB Annual Retreat 2014, Baltimore, MD 
 
Chen, H., Bailey, S. Biochemical Characterization of Streptococcus thermophilus Cas9. Oral 
presentation, JHSPH BMB Colloquium 2013, Baltimore, MD 
 
Chen, H., Choi, J., Bailey, S. Functional study of Cas9 in RNA-guided DNA cleavage. Poster 
presentation, JHSPH BMB Annual Retreat 2013, Baltimore, MD 
 
Chen, H., Bailey, S. Functional studies of Type II CRISPR/Cas system. Oral presentation, 
JHSPH BMB Annual Retreat 2012, Baltimore, MD 
 
Chen, H., Estrella, M., Mulepati, S., Bailey, S. CRISPR: the prokaryotic defense system. JHU 
Institute for Biophysical Research Annual Retreat 2011, Baltimore, MD 
 
MENTORING & TEACHING EXPERIENCES 
 
Fall, 2015                         Elmer A. Zapata-Mercado (Biophysics Rotation student, co-mentored        
                                         with John Mallon) 
Spring, 2015                     Melesse Nune (Biophysics Rotation student) 
Fall, 2014                         Miranda Russo (Biophysics Rotation student) 
Fall, 2013                         Jessica Hopkins (BMB Rotation student)  
Fall, 2011                         Tutor, Biophysical and Biochemical Principles 
 
SCHOLARSHIPS AND AWARDS  
 
2010                                  Thermo Fisher Scientific STEM Scholarship, Fudan University 
2008, 2009                        First Class Merit Scholarship, Fudan University 
2008                                  Fosun Pharma Scholarship, Fudan University 
2008                                  Fung Scholar, University of Hong Kong  
2007                                  Chinese National Scholarship, Fudan University 
2006                                  Tan Jiazhen (C. C. Tan) Life Sciences Scholarship, Fudan University 
 
 
